Poster Presentations

POSTER PRESENTATIONS SESSION III
SET-UP:	Tuesday, 27 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Tuesday, 27 October, 8:00 – 16:00
POSTER AUTHOR DISCUSSION HOUR:	Tuesday, 27 October, 11:00 – 12:00
DISMANTLE:	Tuesday, 27 October, 16:00 – 16:30

CONCEPTUAL PAPERS & RESEARCH ON METHODSClinical Outcomes Methods

PMC1	CORRECTING AN UNDERESTIMATE OF INCREMENTAL COST EFFECTIVENESS RATIO CONSIDERING STATISTICAL ERRORS AND PROBABILITY OF TRUTH
	Kamae I¹, Moriwaki K², Kamae M³ ¹Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, ²Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, ³Tufts-New England Medical Center, Boston, MA, USA

PMC2	A STANDARDIZED EVIDENCE BASED APPROACH TO ASSESS NON-TRADITIONAL OUTCOME MEASURES FOR USE IN HEALTH CARE DECISION MAKING: THE DIABETES EXAMPLE
	Badia X¹, Vieta A¹, Sacristán JA² ¹HEOR IMS Health, Barcelona, Spain, ²Clinical Research Department Lilly, Madrid, Spain

PMC3	CRITICAL REVIEW OF PUBLISHED COST EFFECTIVENESS ANALYSES OF ORAL TRIPTANS IN THE MANAGEMENT OF ACUTE MIGRAINE: DIFFERENT MEASURES OF EFFICACY EXTRACTED FROM THE SAME META-ANALYSIS
	Peura P, Purmonen T, Martikainen JA, Turunen JH University of Kuopio, Kuopio, Finland

PMC4	LARGELY IGNORED: THE IMPACT OF THE THRESHOLD VALUE FOR A QALY ON THE IMPORTANCE OF A TRANSFERABILITY FACTOR
	Vemer P, Rutten-van Molken M Erasmus MC, Rotterdam, The The Netherlands

PMC5	MEASURING AND MONITORING THE REAL-WORLD COST-EFFECTIVENESS OF NEW TECHNOLOGIES IN HOSPITALS
	Neurohr C, Welte R GlaxoSmithKline, Munich, Germany

PMC6	THE NATURE AND SCALE OF INADEQUATE REPORTING OF CONTINUOUS OUTCOMES FROM FOUR SYSTEMATIC REVIEWS
	Singh N, Dimri S, Mahajan A, Agrawal R, Ubhadiya BS, Narvilkar P, Bhanderi M Heron Health Private Ltd, Chandigarh, India

PMC7	THE NATURE AND SCALE OF INADEQUATE REPORTING OF DICHOTOMOUS OUTCOMES FROM SIX SYSTEMATIC REVIEWS
	Bhanderi M, Dimri S, Mahajan A, Ubhadiya BS, Narvilkar P, Agrawal R, Singh N Heron Health Private Ltd, Chandigarh, India

PMC8	USING ATLAS.TI AS A TOOL TO EXTRACT AND SYNTHESIZE DATA OBTAINED IN LITERATURE REVIEWING
	Stafford M¹, Houghton K¹, Stull D² ¹United BioSource Corporation, London, UK, ²United BioSource--Europe, London, UK

PMC9	REDUCING BIAS IN A RETROSPECTIVE CASE-CONTROL STUDY: AN APPLICATION OF PROPENSITY SCORE MATCHING.
	Exuzides A¹, Colby C¹, Goldman J², Waaler A³ ¹ICON Clinical Research, San Francisco, CA, USA, ²ICON Medical Imaging, San Francisco, CA, USA, ³GE Healthcare, Horten, Norway

PMC10	HOW TO MAKE USE OF AVAILABLE SURVIVAL EVIDENCE IN AN INDIRECT COMPARISON
	Ouwens M¹, Philips Z² ¹Mapi Values Netherlands B.V., Houten, The Netherlands, ²Mapi Values UK, Bollington , Cheshire, UK

CONCEPTUAL PAPERS & RESEARCH ON METHODSCost Methods

PMC11	IMPUTE INCOMPLETE PATIENT-LEVEL MEDICAL COSTS
	Guan S¹, Peeters P², Pedotti P¹, Van Engen AK¹ ¹Quintiles Consulting, Hoofddorp, The Netherlands, ²Quintiles Consulting, Levallois-Perret, France

PMC12	DEVELOPMENT OF COST CATALOGS FOR COST-EFFECTIVENESS ANALYSES IN GERMANY: RESULTS OF A FEASIBILITY STUDY
	Scheuringer M, Krobot KJ MSD Sharp & Dohme GmbH, Haar, Germany

PMC13	INDIRECT COST OF ILLNESS IN POLISH ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES
	Wrona W¹, Golicki D¹, Goszczynska K², Wojcik R³, Niewada M⁴, Jakubczyk M¹, Macioch T¹, Hermanowski T¹ ¹Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, ²Medical University of Warsaw, Warszawa, Poland, ³Medical University of Warsaw, Warsaw, Poland, ⁴Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

PMC14	THE COST OF ABSENTEEISM IN POLAND IN 2007 – DIFFERENCES WITHIN THE PROVINCES
	Macioch T, Jakubczyk M, Wrona W, Golicki D, Hermanowski T, Niewada M Medical University of Warsaw, Warsaw, Poland

PMC15	A STANDARD COST TOOLKIT FOR ECONOMIC EVALUATIONS OF CANCER CARE IN FRANCE
	Baffert S¹, Alfonsi A², Florentin V², Livartowski A¹ ¹Institut Curie, Paris , France, ²Roche, Neuilly sur Seine, France

PMC16	QUALITY ASSESSMENT OF PUBLISHED HEALTH ECONOMIC ANALYSES FROM CHINA
	Kaas C¹, Jing L², Bao Y³, Hemels M⁴ ¹Copenhagen University, Copenhagen, Denmark, ²Novo Nordisk (China) Pharmaceuticals Co. Ltd, Beijing, China, ³China Center for Pharmacoeconomics & Outcomes Research, Beijing, China, ⁴Novo Nordisk A/S, bagsværd, Denmark

PMC17	SHOULD INDIRECT COSTS OF ILLNESS BE INCLUDED IN PHARMACOECONOMIC ANALYSIS: SURVEY AMONG POLISH DECISION MAKERS AND EXPERTS
	Wrona W¹, Golicki D¹, Jakubczyk M¹, Niewada M², Czech M¹, Macioch T¹, Hermanowski T¹ ¹Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, ²Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

PMC18	ANALYSIS OF TRANSFERABILITY TOOLS FOR COST-EFFECTIVENESS DATA AND COSIDERATION IN KOREA SETTINGS
	Jung S¹, Lee EK² ¹Graduate School of Clinical Pharmacy, Seoul, South Korea, ²Sook Myung Women's University, Seoul, South Korea

PMC19	VALIDATION OF AN ONLINE INCREMENTAL COST-EFFECTIVENESS CALCULATOR STRUCTURED AS A DECISION ANALYTIC TREE THAT IMPLEMENTS MONTE CARLO SIMULATIONS OF KEY VARIABLES
	McGhan WF, Willey VJ, Peterson AM, Manke AA, Patel DD, Ajmera MR, Patel TB University of the Sciences, Philadelphia, PA, USA

PMC20	IMPLEMENTING A BENCHMARKING MODEL FOR EXPENDITURES OF PRESCRIPTION DRUGS IN AUSTRIA
	Heiderer B, Ortner T, Pfeffer N Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria

PMC21	REAL AND THEORETICAL COST OF ABSENTEEISM IN POLAND
	Macioch T, Hermanowski T, Jakubczyk M, Wrona W, Golicki D, Niewada M Medical University of Warsaw, Warsaw, Poland

PMC22	DEVELOPMENT OF A SENSITIVE RESOURCE USE QUESTIONNAIRE
	Daeppen JB¹, Kopp P², Armand C³, Guennec M⁴, Cochran J³ ¹CHUV, Lausanne, Switzerland, ²Panthéon-Sorbonne (Paris I) University, Paris, France, ³Lundbeck SAS, Paris, France, ⁴Université Victor Segalen (Bordeaux 2), Bordeaux , France

PMC23	UNDERESTIMATION OF UNCERTAINTY IN COST-EFFECTIVENESS ACCEPTABILITY CURVES AND EXPECTED VALUE OF INFORMATION ANALYSES
	Müller D¹, Gandjour A² ¹Universität Witten/Herdecke, Köln, Germany, ²Louisiana State University, Baton Rouge, LA, USA

PMC24	SAMPSON: A HYBRID SIMULATION AND OPTIMIZATION MODEL FOR MANAGING SURGICAL RESOURCES AND REDUCING WAITING TIMES
	Walker HD, Anderson MN Walker Economics, Kingston,, ON, Canada

PMC25	CLINICAL HISTORY, RESOURCE UTILIZATION, AND OTHER PATIENT-REPORTED OUTCOMES (PROS) IN MIGRAINEURS: AN ADAPTABLE WEB-BASED METHODOLOGY FOR THE DESIGN, IMPLEMENTATION AND CONDUCT OF A MULTI-NATIONAL SURVEY OF PATIENTS
	Payne KA¹, Wilcox TK², Yeomans K¹, Kawata AK², Varon SF³, Burk CT⁴, Lipton RB⁵, Blumenfeld A⁶ ¹United BioSource Corporation, Montreal, QC, Canada, ²United BioSource Corporation, Bethesda, MD, USA, ³Allergan Inc., Irvine, CA, USA, ⁴Caroline Burk Inc., Laguna Beach, CA, USA, ⁵Albert Einstein College of Medicine, Bronx, NY, USA, ⁶The Headache Center of Southern California, Del Mar, CA, USA

CONCEPTUAL PAPERS & RESEARCH ON METHODSDatabases & Management Methods
PMC26	LINKING PERSON-LEVEL INPATIENT DATA TO LONGITUDINAL RECORDS
	Huse D¹, Curkendall S² ¹Thomson Reuters, Cambridge, MA, USA, ²Thomson Reuters, Washington DC , DC, USA

PMC27	IDENTIFYING ECONOMIC EVALUATIONS IN MEDLINE AND EMBASE: HOW WELL DO PUBLISHED SEARCH FILTERS PERFORM?
	Glanville J¹, Kaunelis D², Mensinkai S² ¹York Health Economics Consortium Ltd, York, North Yorks, UK, ²Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada

PMC28	EXPERT SURVEY FOR INCREMENTAL COST-EFFECTIVENESS RATIO (ICER) THRESHOLD RANGE IN KOREA: DISCRETE CHOICE EXPERIMENTS
	Lee J, Ko S Pfizer Korea, Seoul, South Korea

PMC29	IMPACT OF MISSING DATA ON POTENTIAL CONFOUNDERS IN PERINATAL PHARMACOEPIDEMIOLOGIC STUDIES USING ADMINISTRATIVE DATABASES
	Bérard A, Nakhai-Pour HR, Kulaga S University of Montreal, Montreal, QC, Canada

PMC30	HOW TO GAIN HIGH DATA QUALITY IN A NON-INTERVENTIONAL TRIAL TAKING THE LIVE-COM STUDY AS EXAMPLE
	Schön H¹, Theobald K², Schädlich PK³ ¹CSG mbH, Berlin, Germany, ²Sanofi-Aventis Germany, Frankfurt, Germany, ³IGES Institut GmbH, Berlin, Germany

PMC31	THE MONDRIAAN PROJECT: THE DUTCH HEALTHCARE LANDSCAPE AS A POPULATION LABORATORY
	Klungel OH¹, Rietveld MC², de Groot MC³, Stolk RP⁴, Postma MJ⁵, Leufkens HG¹, Egberts TC³, Hövels AM⁶, van de Langerijt L⁷, Hoes AW³, Grobbee DE³ ¹Utrecht University, Utrecht, The Netherlands, ²University Medical Center Utrecht, Utrecht,, The Netherlands, ³University Medical Center Utrecht, Utrecht, The Netherlands, ⁴University Medical Center Groningen, Groningen, The Netherlands, ⁵University of Groningen, Groningen, The Netherlands, ⁶GlaxoSmithKline The Netherlands, Zeist, The Netherlands, ⁷Sanofi-aventis The Netherlands B.V, Gouda, The Netherlands

CONCEPTUAL PAPERS & RESEARCH ON METHODSModeling Methods
PMC32	MULTI AGENT SIMULATION TECHNIQUES FOR DYNAMIC SIMULATION OF SOCIAL INTERACTION AND SPREAD OF DISEASES WITH DIFFERENT SEROTYPES
	Endel G¹, Schiller - Frühwirth I¹, Popper N², Miksch F², Zauner G², Breitenecker F³ ¹Hauptverband der Österreichischen Sozialversicherungsträger, Vienna, Vienna, Austria, ²DWH - Simulation Services, Vienna, Vienna, Austria, ³Vienna University of Technology, Vienna, Vienna, Austria

PMC33	CRITICAL REVIEW OF ECONOMIC MODELS IN TYPE 2 DIABETES
	Yi Y¹, Bergman G², Burslem K³, Philips Z⁴ ¹Mapi Values, Cheshire, UK, ²Mapi Values, Houten, The Netherlands, ³Boehringer Ingelheim Limited, Berkshire, UK, ⁴Mapi Values, Macclesfield, UK

PMC34	SEROTYPE-SPECIFIC TRANSMISSION DYNAMICS OF INVASIVE PNEUMOCOCCAL DISEASE AFTER VACCINATION WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
	Snedecor SJ¹, Botteman MF¹, Strutton DR² ¹Pharmerit North America LLC, Bethesda, MD, USA, ²Wyeth Research, Collegeville, PA, USA

PMC35	SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION
	Dragomir A¹, Angers JF¹, Tarride JE², Rouleau G¹, Drapeau P¹, Perreault S¹ ¹University of Montreal, Montréal, QC, Canada, ²McMaster University, Hamilton, ON, Canada

PMC36	CREATING NATIONAL WEIGHTS FOR PRIVATE INSURANCE DATABASE
	Baser O¹, Wang L² ¹University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research, Ann Arbor, MI, USA

PMC37	COMPARISON OF RISK ADJUSTMENT MODELS IN OUTCOMES RESEARCH
	Baser O¹, Gust C², Dysinger A², Yuce H³, Akin C¹, Wang L² ¹University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research, Ann Arbor, MI, USA, ³STATinMED Research and The City University of New York, Brooklyn, NY, USA

PMC38	COMPARISON OF TWO METHODS TO DETERMINE COSTS FOR AML PATIENTS IN REMISSION: MODEL VALIDATION FROM A UK PERSPECTIVE
	Purdy C¹, Magar RS², Hayward A¹, Einarson TR³ ¹AHRM Inc., Buffalo, NY, USA, ²AHRM Inc., Raleigh, NC, USA, ³University of Toronto, Toronto, ON, Canada

PMC39	USING MIXED TREATMENT COMPARISON MODELING TO COMPARE PROPORTIONS OF NAIVE HBEAG(+) CHB PATIENTS WHO ACHIEVED UNDETECTABLE HBV DNA
	Diva UA, Cross AP, Brett-Smith H Bristol-Myers Squibb, Wallingford, CT, USA

PMC40	ESTIMATING THE NET HERD EFFECT INDUCED BY PCV-VACCINES: A HYPOTHESIS GENERATING STUDY
	Sauboin C, Knerer G, Standaert B GlaxoSmithKline Biologicals, Rixensart, Belgium

PMC41	CONTROLLING FOR UNOBSERVABLE BIAS: IS THE CURE WORSE THAN THE DISEASE?
	Baser O¹, Dysinger A² ¹University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research, Ann Arbor, MI, USA

PMC42	COMPARING MARKOV MODEL AND DES – THE EXAMPLE OF COPD
	Jaburg AF¹, Rottenkolber D¹, Menn P² ¹Ludwig-Maximilians-Universität Munich, Munich, Germany, ²Institute of Health Economics & Health Care Management, Helmholtz Center Munich, Neuherberg, Germany

PMC43	A CONCEPTUAL FRAMEWORK TO APPLY DISCRETE-EVENT SIMULATION TO ESTIMATE THE RESOURCES NEEDED TO PERFORM A POPULATION BASED CANCER SCREENING PROGRAM
	Comas M¹, Roman R¹, Mar J², Casamitjana M¹, Castells X¹ ¹Hospital del Mar (IMAS), Barcelona, Spain, ²Hospital 'Alto Deba', Mondragon, Spain

PMC44	MODELLING THE UPTAKE AND DIFFUSION OF INNOVATIVE TECHNOLOGY: A CRITICAL AND STRATEGIC FEATURE OF BUDGET IMPACT ANALYSIS AND RISK-SHARING AGREEMENTS
	Ethgen O, Hiligsmann M, Reginster JY University of Liège, Liège, Belgium

PMC45	REVIEWER'S CHECKLIST FOR ASSESSING THE QUALITY OF DECISION MODELS
	Zimovetz E, Wolowacz SE RTI Health Solutions, Manchester, UK

PMC46	BAYESIAN CALIBRATION OF A NATURAL HISTORY MODEL FOR COLORECTAL CANCER
	Whyte S¹, Walsh C², Sharp L³, O'Ceilleachair A⁴, Tilson L⁵, Usher C⁵, Chilcott J⁶, Tappenden P⁷, Staines A⁸, Comber H⁴, Barry M⁵ ¹School for Health and Related Research, Sheffield, UK, ²Trinity College Dublin, Dublin, Ireland, ³National Cancer Registry of Ireland, Cork, NA, Ireland, ⁴National Cancer Registry of Ireland, Cork, Ireland, ⁵National Centre for Pharmacoeconomics, Dublin, Ireland, ⁶School for Health and Related Research, Sheffield, UK, ⁷University of Sheffield, Sheffield, UK, ⁸School of Nursing, Dublin, Ireland

PMC47	WILLINGNESS TO INITIATE THERAPY AND PUBLIC HEALTH POLICY: AN APPLICATION TO THE STRATEGIC DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR HEPATITIS C TREATMENT
	Kauf TL¹, Grant WC² ¹University of Florida, Gainesville, FL, USA, ²James Madison University, Harrisonburg, VA, USA

PMC48	A DYNAMIC MODEL TO MAXIMIZE THE HELATH BENEFITS IN MUTUALLY EXCLUSIVE SUSCEPTIBLE INFECTIOUS POPULATION
	Chang CJ¹, Wu D², Lin YJ³, Wang PC⁴, Fann CS⁵ ¹Chang Gung University, Taoyuan, Taiwan, ²National Yang-Ming University, Taipei, Taiwan, ³Chang Gung University, Tao Yuan, Taiwan, ⁴Cathay General Hospital, Taipei, Taiwan, ⁵Academia Sinica, Taipei, Taiwan

CONCEPTUAL PAPERS & RESEARCH ON METHODSPatient-Reported Outcomes Studies
PMC49	SENSITIVITY OF 15D, EQ-5D AND SF-6D TO DIABETES COMPLICATIONS: THE CASE OF CORONARY HEART DISEASE
	Kontodimopoulos N¹, Arvanitaki-Vasilakaki E², Chadjiapostolou Z³, Niakas D¹ ¹Hellenic Open University, Patras, Greece, ²Ag. Varvara Health Centre, Heraklion Crete, Greece, ³Mamatseio General Hospital, Kozani, Greece

PMC50	MEASUREMENT OF OUTPATIENT REHABILITATION OUTCOMES WITH EQ-5D
	Reinders S¹, Rasch A¹, Haupts M², Greiner W¹ ¹University of Bielefeld, Bielefeld, Germany, ²ZAR Bielefeld GmbH, Bielefeld, Germany

PMC51	PATIENT COMPLETION OF EPROS: TO PHONE OR TO WEB?
	Miller KL¹, Jenkins E², Silva S¹, Welle J¹, Collier K², McCoy D³, Lubeck DP¹ ¹ICON Clinical Research, San Francisco, CA, USA, ²ICON Clinical Research, Sugar Land, TX, USA, ³ICON Clinical Research, North Wales, PA, USA

PMC52	ASSESSING THE (DIS) AGREEMENT OF EQ-5D AND SF-6D ACROSS GROUPS WITH INCREASING SEVERITY OF CHRONIC HEART FAILURE
	Kontodimopoulos N¹, Argiriou M², Theakos N², Niakas D¹ ¹Hellenic Open University, Patras, Greece, ²Evangelismos Hospital, Holargos Athens, Greece

PMC53	HFS 14: A SPECIFIC QUALITY OF LIFE INSTRUMENT FOR PATIENTS WITH HAND-FOOT SYNDROME
	Taieb C¹, Sibaud V² ¹PFSA, Boulogne, France, ²Institut Claudius Regaud,, Toulouse, France

PMC54	ESTIMATING SOCIAL PREFERENCES FOR EQ-5D IN TURKEY : A NOVEL METHOD BASED ON A VALUATION EXCHANGE-RATE MECHANISM
	Chuang LH¹, Malhan S², Oksuz E², Kind P¹ ¹University of York, York, UK, ²Baskent University, Ankara, Turkey

PMC55	AGREEMENT BETWEEN PATIENT AND PROXY ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BEFORE INTENSIVE CARE UNIT ADMISSION
	Vandijck D¹, Oeyen S², Costers S¹, Annemans L¹, Decruyenaere J² ¹Ghent University, Ghent, Belgium, ²Ghent University Hospital, Ghent, Belgium

PMC56	PREFERENCES FOR PREFERENCES
	Greenberg D, Fang C, Cohen JT, Neumann PJ Tufts Medical Center, Boston, MA, USA

PMC57	TO MAP OR NOT TO MAP? THE OXFORD HIP SCORE AND EQ-5D COMPARED
	Oppe M¹, Devlin N² ¹Erasmus MC, Rotterdam, The Netherlands, ²Office of Health Economics, London, UK

PMC58	EVALUATING THE INFLUENCE OF PHYSICAL ACTIVITY ON THE SOCIAL AND ENVIRONMENTAL DOMAINS OF QUALITY OF LIFE
	Lin WL, Yao G National Taiwan University, Taipei, Taiwan

PMC59	CULTURAL AND LINGUISTIC ISSUES ASSOCIATED WITH THE TRANSLATION AND LINGUISTIC VALIDATION OF QUESTIONNAIRES FOR USE IN CHINA
	Houchin C, Wild D Oxford Outcomes Ltd, Oxford, UK

PMC60	WILLINGNESS TO PAY FOR HEALTH INTERVENTIONS: BASED ON SYSTEMATIC REVIEW OF LITERATURES
	Lee J¹, Park D², Ko S¹ ¹Pfizer Korea, Seoul, South Korea, ²Seoul National University, Seoul, South Korea

PMC61	CATALOGUE OF EQ-5D SCORES FOR THE UNITED KINGDOM
	Sullivan PW¹, Sculpher MJ², Ghushchyan VH³, Slejko JF³ ¹Regis University, Denver, CO, USA, ²University of York, York, UK, ³University of Colorado Denver, Aurora, CO, USA

PMC62	ONLINE ADMINISTRATION OF THE TIME TRADE-OFF: A CASE-STUDY AMONG PEOPLE WITH RESTLESS LEGS SYNDROME
	Aballéa S¹, Quilici S², Roïz J³ ¹i3 Innovus, Nanterre, France, ²i3 Innovus, Uxbridge, Middlesex, UK, ³i3 Innovus, Uxbridge, UK

PMC63	IS EXTENDING OF TIME TRADE-OFF EXPERIMENT TO 23 STATES PER RESPONDENT RATIONALIZED? ANALYSIS OF DATA FROM POLISH VALUATION STUDY
	Golicki D¹, Jakubczyk M¹, Niewada M², Wrona W¹, Busschbach JJ³, Macioch T¹, Hermanowski T¹ ¹Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, ²Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland, ³Erasmus Medical Center, Rotterdam, The Netherlands

PMC64	DIFFICULTIES WITH THE APPLICATION OF PRO MEASURES TO CULTURES OUTSIDE OF WESTERN EUROPE AND NORTH AMERICA IN MULTI-NATIONAL TRIALS
	Furtado T, Houchin C, Wild D Oxford Outcomes Ltd, Oxford, UK

PMC65	QUALITATIVE METHODS IN PRO RESEARCH: DEVELOPMENT OF A METHODS MATRIX
	Nixon A, Wild D Oxford Outcomes Ltd, Oxford, UK

PMC66	THE ADVANTAGES OF A CENTRALIZED DISSEMINATION STRATEGY FOR HEALTH OUTCOMES INSTRUMENTS AND THEIR TRANSLATIONS: A CASE EXAMPLE WITH THE ZARIT BURDEN INTERVIEW (ZBI)
	Anfray C¹, Emery MP¹, Zarit S² ¹MAPI Research Trust, Lyon, France, ²Pennsylvania State University, University Park, PA, USA

PMC67	LINGUISTIC ADAPTATION OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) INTO ENGLISH
	Ruiz MA¹, Rejas J², Pardo A¹, Soto J² ¹Universidad Autónoma de Madrid, Madrid, Spain, ²Pfizer Spain, Madrid, Spain

PMC68	CORRELATION BETWEEN ADHERENCE RATES MEASURED BY MEDICATION EVENT MANAGEMENT SYSTEM AND SELF-REPORTED QUESTIONNAIRES: A META-ANALYSIS
	Shi L¹, Liu J¹, Walker PD¹, Fonseca V¹, Kalsekar A², Pawaskar MD² ¹Tulane University, New Orleans, LA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PMC69	EXAMINING MASLOW'S HIERARCHICAL THEORY OF NEEDS BY USING THE ITEMS OF THE WHOQOL-BREF
	Yao G, Lin WL National Taiwan University, Taipei, Taiwan

PMC70	CLASSIFYING PATIENT REPORTED OUTCOMES: DEVELOPMENTS IN THE FIELD SUGGEST A NEW TAXONOMY
	Lloyd A¹, Bridges JF², Johnson FR³ ¹Oxford Outcomes Ltd, Oxford, UK, ²Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, ³RTI Health Solutions, Research Triangle Park, NC, USA

PMC71	THE EVOLVING HEALTH ECONOMICS EVALUATION PARADIGM AND THE ROLE OF THE QALY
	Schlander M¹, Richardson J² ¹Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany, ²Monash University, Clayton, Victoria, Australia

PMC72	DEVELOPMENT OF THE ACCEPT© QUESTIONNAIRE TO ASSESS ACCEPTABILITY OF LONG TERM TREATMENTS: QUALITATIVE STEPS
	Marant C¹, Spizak C¹, Longin J², Marrel A¹, Van Ganse E³, Arnould B¹, Patrick DL⁴ ¹Mapi Values, Lyon, France, ²Registrat-Mapi, Lyon, France, ³Pierre Wertheimer Hospital, Bron, France, ⁴University of Washington, Seattle, WA, USA

PMC73	DIFFERENT STUDY RESULTS OF UTILITIES IN RELATION TO THE DOCUMENTING METHOD USED AND THE GUARANTEE OF LEGALLY COMPLIANT IQWIG RECOMMENDATIONS WITHIN THE FRAMEWORK OF A COST-BENEFIT ASSESSMENT
	Dintsios CM, Volz F, Seidl A Institute for Quality and Efficiency in Health Care, Cologne, Germany

PMC74	WHICH HEALTH ECONOMIC APPROACHES FOR WHICH DECISION-MAKING SUPPORT IN METASTATIC CANCER ? A LITERATURE REVIEW AND FRENCH EXPERT OPINIONS
	Baffert S¹, Alfonsi A², Florentin V², Livartowski A¹ ¹Institut Curie, Paris Cedex 05, France, ²Roche, Neuilly sur Seine, France

CONCEPTUAL PAPERS & RESEARCH ON METHODSStudy Design
PMC75	ARE ONLINE MANAGED PHYSICIAN PANELS A VIABLE SOURCE FOR SCIENTIFIC RESEARCH INITIATIVES?
	Narayanan S TNS Healthcare, New York, NY, USA

PMC76	PATIENT REGISTRIES – A LITERATURE REVIEW OF RECENTLY REPORTED REGISTRY BASED STUDIES
	Lis Y¹, Bettinelli L², Coward G¹ ¹PAREXEL International, Uxbridge, Middlesex, UK, ²PAREXEL International, Berlin, Germany

POSTER PRESENTATIONS SESSION III
SET-UP:	Tuesday, 27 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Tuesday, 27 October, 8:00 – 16:00
POSTER AUTHOR DISCUSSION HOUR:	Tuesday, 27 October, 11:00 – 12:00
DISMANTLE:	Tuesday, 27 October, 16:00 – 16:30

DIABETES/ENDOCRINE DISORDERS Clinical Outcomes Studies
PDB1	A COMPARISON OF CLINICAL EFFICACY OF INSULIN GLARGINE ADDED TO ORAL ANTIDIABETIC DRUGS VS PREMIXED INSULINS ALONE IN THE TREATEMENT OF TYPE-2 DIABETES MELLITUS
	Rogoz A¹, Kucia K¹, Skowron M¹, Rys P¹, Siejka S¹, Palka I¹, Gierczynski J², Plisko R¹, Wladysiuk M¹ ¹HTA Consulting, Krakow, Poland, ²Sanofi-Aventis sp. z o.o, Warszawa, Poland

PDB2	REAL WORLD CLINICAL EFFECTIVENESS OF SITAGLIPTIN THERAPY FOR MANAGEMENT OF TYPE 2 DIABETES: A RETROSPECTIVE DATABASE ANALYSIS
	Wade R¹, Pawaskar MD², Quimbo RA¹, Hou L¹ ¹HealthCore, Inc., Wilmington, DE, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PDB3	FORECASTING THE NUMBER OF DIABETIC PATIENS IN THE UNITED STATES IN 2050
	Baser O¹, Wang L², Gust C² ¹University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research, Ann Arbor, MI, USA

PDB4	LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM BIPHASIC INSULIN TO BIPHASIC INSULIN ASPART 30/70: AN IMPROVE STUDY SUBGROUP ANALYSIS
	Ligthelm R¹, Christensen TE², Thomsen TL², Yang W³ ¹EHM, Hoofddorp, The Netherlands, ²Novo Nordisk A/S, Virum, Denmark, ³China-Japan Friendship Hospital, Beijing, Beijing, China

PDB5	SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF VILDAGLIPTIN FOR TYPE 2 DIABETES MELLITUS
	Walczak J, Nogas G, Organa M, Przada P, Potoczny R Arcana Institute, Cracow, Poland

PDB6	ADMINISTRATIVE CLAIMS ANALYSIS OF AN L-METHYLFOLATE COMBINATION PRODUCT IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY
	Wade R¹, Cai Q¹, Thethi T² ¹HealthCore, Inc, Wilmington, DE, USA, ²Tulane University Health Sciences Center, New Orleans, LA, USA

PDB7	THE CLINICAL EFFECTIVENESS OF SOMATROPIN (GENOTROPIN®) IN CHILDREN WITH SHORT STATURE: A SYSTEMATIC REVIEW
	Heatley RM¹, Walsh C², Loftus J³ ¹Evidence Research Unit, Macclesfield, UK, ²Complete Medical Group, Macclesfield, UK, ³Pfizer Ltd, Walton on the Hill, UK

PDB8	ANTIDIABETIC DRUG UTILIZATION IN A UNIVERSITY HEALTH CARE SETTING
	Mousnad M¹, Ibrahim MIM² ¹Universiti Sains Malaysia, Penang , Malaysia, ²Universiti Sains Malaysia, Penang, Malaysia

PDB9	IMPACT OF FDA SAFETY WARNINGS ON SUBSEQUENT DIABETES CARE FOR USERS OF ROSIGLITAZONE
	Huse D, Bizier R Thomson Reuters, Cambridge, MA, USA

PDB10	DIFFERENT PERSISTENCE WITH A BASAL SUPPORTED ORAL THERAPY (BOT) LEADS TO UNEQUAL DISTRIBUTIONS OF INSULIN TREATMENT REGIMENS IN TYPE-2-DIABETICS
	Reichelt A¹, Pfohl M², Dippel FW³, Pirk O¹, Kotowa W¹ ¹IMS HEALTH GmbH & Co. OHG HEOR, Nuremberg, Germany, ²Evangelisches Bethesda-Johanniter-Klinikum GmbH, Duisburg, Germany, ³Sanofi-Aventis Deutschland GmbH, Berlin, Germany

PDB11	DATABASE ANALYSIS ON PREVALENCE AND RISK FACTORS OF DIABETIC FOOT SYNDROME (DFS) IN GERMANY
	Lauterbach S¹, Kostev K², Kohlmann T³, Schröder-Bernhardi D² ¹Rotes Kreuz Hospital, Kassel, Germany, ²IMS HEALTH GmbH & Co. OHG, Frankfurt am Main, Germany, ³University of Greifswald, Greifswald, Germany

PDB12	GLYCATED HAEMOGLOBIN AS A SURROGATE MARKER FOR THE APPEARANCE AND PROGRESSION OF RETINOPATHY IN TYPE-1 DIABETES MELLITUS: SYSTEMATIC REVIEW AND META-ANALYSIS
	Wieczorek A¹, Marcisz A¹, Rys P¹, Skrzekowska-Baran I², Plisko R¹, Wladysiuk M³ ¹HTA Consulting, Krakow, Poland, ²Novo Nordisk, Inc., Warsaw, Mazowieckie, Poland, ³HTA Consulting, Krakow, Malopolska, Poland

PDB13	MEDICATION PATTERN AND RISK OF STROKE AMONG TYPE II DIABETES MELLITUS IN TAIWAN-A POPULATION-BASED STUDY
	Wu CS¹, Tang CH², Huang HM³ ¹Taipei City Hospital, Zhong Xing Branch, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Taipei City Hospital, Woman and Children Branch, Taipei, Taiwan

DIABETES/ENDOCRINE DISORDERS Cost Studies
PDB14	THE BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN IN TYPE 2 DIABETES IN POLAND
	Walczak J, Nogas G, Gebus E, Pawlik D, Pacocha K Arcana Institute, Cracow, Poland

PDB15	COST OF AN EPISODE OF DIABETIC FOOT ULCER IN SPAIN
	Marinel.lo J¹, March JR², Blanes JI³, Martínez-Aguilar E⁴, Escudero JR⁵, Masegosa A⁶, Lizano C⁷, Massó JM⁷, Yébenes M⁸, Casado MA⁸ ¹Hospital de Mataró, Mataró, Spain, ²Hospital Universitario de Getafe, Getafe, Spain, ³Hospital Universitario Dr. Peset, Valencia, Spain, ⁴Hospital de Navarra, Pamplona, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Complejo Hospitalario Universitario de Albacete, Albacete, Spain, ⁷Praxis Pharmaceutical, Madrid, Spain, ⁸Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain

PDB16	GLYCEMIC CONTROL IN THE INPATIENT SETTING: INSULIN ASPART COMPARED TO HUMAN BOLUS INSULIN
	Ko K¹, Tomor V², Bouchard JR², Aagren M², Dubois R¹ ¹Cerner LifeSciences, Beverly Hills, CA, USA, ²Novo Nordisk, Inc., Princeton, NJ, USA

PDB17	TREATMENT COSTS ATTRIBUTABLE TO BEING OVERWEIGHT OR OBESE IN U.S. DIABETIC PATIENTS: QUANTILE REGRESSION APPROACH
	Suh DC¹, Choi IS¹, Kwon JW¹, Jang SM², Jang EJ¹, Barone JA¹ ¹Rutgers University, Piscataway, NJ, USA, ²Health Insurance Review & Assessment Service, Seoul, South Korea

PDB18	COST OFFSETS ASSOCIATED WITH USE OF EXENATIDE COMPARED TO GLARGINE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
	Pawaskar MD¹, Anderson J¹, Zagar AJ² ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Lilly USA, LLC, Indianapolis, IN, USA

PDB19	TIME TO OPIOID USE AND HEALTH CARE COSTS AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS
	Zhao Y¹, Chen SY², Boulanger L², Fraser K², Wu N² ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA

PDB20	A COST CONSEQUENCE MODEL TO ASSESS THE ECONOMIC IMPACT IN GERMANY OF PATIENTS ACHIEVING KDOQITM TARGETS WITH THE USE OF A COMBINATION OF CINACALCET + TRADITIONAL THERAPY (TT) COMPARED WITH TT ALONE
	Ho J¹, Kwan R², Chiroli S³, Steinle T⁴ ¹Dymaxium Inc., Toronto, Ontario , Canada, ²Dymaxium Inc., Toronto, Ontario, Canada, ³Amgen, Zug, Switzerland, ⁴Amgen GmbH, Munich, Germany

PDB21	WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS
	Goeree RA, Lim ME, Hopkins R, Blackhouse G, Tarride JE, Xie F, O'Reilly D McMaster University, Hamilton, ON, Canada

PDB22	Self-Monitoring of Blood Glucose (SMBG) for Type 2 Diabetes Patients on Oral Anti-Diabetes Drugs (OADs): Cost-Effectiveness in France, Germany, Italy and Spain
	Tunis S¹, Willis WD² ¹IMS Consulting Services, Falls Church, VA, USA, ²LifeScan, Inc., High Wycombe, Bucks, UK

PDB23	PREDICTING COST-EFFECTIVENESS OF A DIABETES HEALTH CARE PROGRAM IN BELGIUM AS A POLICY MANAGEMENT TOOL
	Benoit K¹, Bastiaens H², Sunaert P¹, Annemans L¹ ¹Ghent University, Ghent, Belgium, ²Antwerp University, Wilrijk, Belgium

PDB24	COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING
	Suchankova E¹, Doležal T¹, Pisarikova Z¹, Rychna K², Bartaskova D³ ¹Charles University, Prague , Czech Republic, ²Novo Nordisk s.r.o, Praha 6, Czech Republic, ³2nd Medical faculty Charles University, Prague, Czech Republic

PDB25	A PATIENT-LEVEL SIMULATION MODEL FOR ECONOMIC EVALUATION OF CINACALCET IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN ITALY
	Eandi M¹, Pradelli L², Iannazzo S², Chiroli S³, Pontoriero G⁴ ¹Università degli Studi di Torino, Torino, Italy, ²AdRes HE&OR, Torino, Italy, ³Amgen, Zug, Switzerland, ⁴Alessandro Manzoni Hospital, Lecco, Italy

PDB26	THE PHARMACOECONOMIC STUDY OF INSULIN GLRAGINE USAGE IN ROUTINE CLINICAL PRACTICE IN RUSSIAN FEDERATION
	Kolbin AS¹, Shestakova MV² ¹St. Petersburg State University, Saint-Peterburg, Russia, ²Russian Endocrinological Scientific Center, Moscow, Russia

PDB27	COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE-2 DIABETES IN TURKEY: A LONG-TERM HEALTH ECONOMIC ANALYSIS
	Bruhn D¹, Malhan S², Kavuncubasi S², Smith-Palmer J³, Reed V⁴ ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Baskent University, Ankara, Turkey, ³IMS Health, Basel, Switzerland, ⁴Eli Lilly and Company, Sydney, NSW, Australia

PDB28	THE COST-EFFECTIVENESS ANALYSIS OF VIDALGLIPTIN IN TYPE 2 DIABETES IN POLAND
	Walczak J, Nogas G, Gebus E, Pawlik D, Pacocha K Arcana Institute, Cracow, Poland

PDB29	PHARMACOECONOMIC CONSEQUENCES OF LOSARTAN THERAPY IN PATIENS UNDERGOING DIABETIC END-STAGE RENAL DISEASE
	Citarella A¹, Mantovani LG², Cammarota S¹, Menditto E¹, Riegler S¹, De Portu S² ¹University of Naples, Naples, Italy, ²University Federico II, Naples, Italy

PDB30	CSII COMPARED TO MDI: A HEALTH ECONOMIC ANALYSIS IN THE GERMAN HEALTH CARE SETTING
	Neeser K, Kocher S, Weber C, Heister F Institute for Medical Informatics and Biostatistics, Basel, Switzerland

PDB31	COST-EFFECTIVENESS ANALYSIS OF VOGLIBOSE FOR PREVENTION OF TYPE-2 DIABETES MELLITUS IN JAPANESE INDIVIDUALS WITH IMPAIRED GLUCOSE TOLERANCE
	Ikeda S¹, Kobayashi M², Tajima N³ ¹International University of Health and Welfare, Ohtawara, Tochigi, Japan, ²Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan, ³Jikei University School of Medicine, Minato-ku, Tokyo, Japan

PDB32	COST-EFFECTIVENESS OF NICOTINE REPLACEMENT THERAPY (NRT) FOR SMOKING CESSATION IN PATIENTS WITH CORONARY HEART DISEASE (CHD), DIABETES MELLITUS TYPE 2 (DMT2) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN GERMANY
	Aidelsburger P¹, Lang K¹, Wasem J² ¹CAREM GmbH, Sauerlach, Germany, ²University of Duisburg-Essen, Essen, Germany

PDB33	A COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE-1 DIABETES PATIENTS IN ITALY
	Giardina S¹, Lynch P², Papo NL³ ¹Medtronic Italia, Sesto San Giovanni (MI), Italy, ²Medtronic, Northridge, CA, USA, ³Medtronic International, Tolochenaz, Switzerland

PDB34	LOWER LONG-TERM COSTS IN GERMAN TYPE-2-DIABETICS STARTING A BASAL SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE COMPARED TO NPH-INSULIN
	Kotowa W¹, Reichelt A¹, Pfohl M², Dippel FW³, Pirk O¹ ¹IMS HEALTH GmbH & Co. OHG HEOR, Nuremberg, Germany, ²Evangelisches Bethesda-Johanniter-Klinikum GmbH, Duisburg, Germany, ³Sanofi-Aventis Deutschland GmbH, Berlin, Germany

PDB35	LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE-2 DIABETES PATIENTS ON BASAL-BOLUS THERAPY UNDER REAL WORLD CONDITIONS IN GERMANY
	Bierwirth R¹, Kohlmann T², Dippel FW³, Landgraf W⁴, Holle R⁵ ¹Ambulantes Diabteszentrum am Elisabeth-Krankenhaus, Essen, Germany, ²Ernst Moritz Arndt Universität, Greifswald, Germany, ³Sanofi-Aventis, Berlin, Germany, ⁴TU Dresden, Dresden, Germany, ⁵Helmholtz Centre, Institut für Gesundheitsökonomie und Management im Gesundheitswesen, Neuherberg, Germany

PDB36	COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL-BOLUS TREATMENT CONCEPT IN GERMANY
	Neilson A¹, Pscherer S², Dippel FW³, Dietrich ES¹ ¹HealthEcon AG, Basel, Switzerland, ²Klinikum Traunstein, Traunstein, Germany, ³Sanofi-Aventis, Berlin, Germany
PDB37	COST-MINIMIZATION ANALYSIS COMPARING BASAL ANALOGUE INSULINS IN HUNGARY
	Kosa J Sanofi-Aventis, Budapest, Pest, Hungary

PDB38	COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL SUPPORTED ORAL THERAPY (BOT) IN GERMANY
	Neilson A¹, Pscherer S², Dippel FW³, Dietrich ES¹ ¹HealthEcon AG, Basel, Switzerland, ²Klinikum Traunstein, Traunstein, Germany, ³Sanofi-Aventis, Berlin, Germany

PDB39	ECONOMIC ANALYSIS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 1 DIABETES MELLITUS IN MEXICO
	Reyes-Lopez A¹, Lemus A², Acevedo GAR³ ¹Children Hospital of Mexico, Mexico City, Mexico, ²Sanofi-aventis de México, Mexico City, D.F, Mexico, ³Hospital Carlos Mc Gregor Sánchez Navarro. IMSS, Mexico City, Mexico

PDB40	COST-UTILITY OF BIPHASIC INSULIN ASPART COMPARED WITH PREMIXED HUMAN INSULIN IN TREATMENT OF TYPE-2 DIABETES MELLITUS IN POLAND
	Szmurlo D¹, Gurda-Duda A¹, Rys P¹, Rutkowski J¹, Skrzekowska-Baran I², Plisko R¹, Wladysiuk M¹ ¹HTA Consulting, Krakow, Poland, ²Novo Nordisk, Inc., Warsaw, Mazowieckie, Poland

PDB41	COST-UTILITY OF INSULIN GLARGINE IN COMBINATION THERAPY WITH ORAL AGENTS COMPARED WITH PREMIX INSULIN WITH OR WITHOUT OF ORAL AGENTS IN TYPE 2 DIABETES. THE POLISH PERSPECTIVE
	Dziewiatka M¹, Kostrzewska K¹, Krzystek J¹, Wilk D¹, Wladysiuk M¹, Lis J², Plisko R¹, Rys P¹ ¹HTA Consulting, Krakow, Poland, ²Sanofi-Aventis, Warsaw, Poland


DIABETES/ENDOCRINE DISORDERS Patient-Reported Outcomes Studies
PDB42	INSULIN ADMINISTRATION WITH FLEXPEN® IS ASSOCIATED WITH INCREASED ADHERENCE AND NO ADDED COSTS TO PAYERS IN A US MANAGED CARE SETTING
	Henk HJ¹, Baser O², Christensen TE³, Bouchard JR⁴, Aagren M⁴ ¹i3 Innovus, Eden Prairie, MN, USA, ²University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ³Novo Nordisk A/S, Virum, Denmark, ⁴Novo Nordisk, Inc., Princeton, NJ, USA

PDB43	MEDICATION ADHERENCE IN LOW INCOME ELDERLY TYPE 2 DIABETES PATIENTS: A RETROSPECTIVE COHORT STUDY
	Patel I¹, Chang J¹, Shenolikar RA², Balkrishnan R¹ ¹University of Michigan, Ann Arbor, MI, USA, ²GlaxoSmithKline, Durham, NC, USA

PDB44	EXAMINING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND MEDICATION ADHERENCE IN DIABETIC PATIENTS
	Pinto SL, Holl S The University of Toledo, Toledo, OH, USA

PDB45	ASSESSING UTILITIES AND DISUTILITIES FOR TYPE 2 DIABETES TREATMENT-RELATED ATTRIBUTES IN AN ASIAN POPULATION
	Bruhn D¹, Gibbs M², Jung RC³, Kalsekar A¹ ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Information Fulfillment Ltd., Shanghai, China, ³Eli Lilly and Company, Korea, Seoul, South Korea

PDB46	UTILITIES FOR INFUSION THERAPY IN TYPE 1 DIABETES
	Lloyd A¹, Swinburn P¹, Boye KS², Curtis BH², Sarpong E², Goldsmith K³, Bode BW⁴, Aronoff S⁵ ¹Oxford Outcomes Ltd, Oxford, UK, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Institute of Public Health, Cambridge, UK, ⁴Atlanta Diabetes Associates, Atlanta, GA, USA, ⁵Endocrine Associates of Dallas P.A, Plano, TX, USA

PDB47	HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES OVER THE 24 MONTHS FOLLOWING INITIATION OF INSULIN
	Meadows K¹, Smith HT², Nicolay C³ ¹North East London Consortium for Research and Development (NELCRAD), London, UK, ²Eli Lilly and Company, Surrey, UK, ³Eli Lilly and Company, Bad Homburg, Germany

PDB48	ASSESSING THE MINIMUM CLINICALLY IMPORTANT DIFFERENCE OF THE WORRY SCALE OF THE HYPOGLYCAEMIA FEAR SURVEY IN PATIENTS WITH TYPE 2 DIABETES
	Stargardt T¹, Gonder-Frederick L², Krobot KJ³, Alexander CM⁴ ¹Helmholtz Zentrum Muenchen, Neuherberg, Germany, ²University of Virginia, Charlottesville, VA, USA, ³MSD Sharp & Dohme GmbH, Haar, Germany, ⁴Merck, White House Station, NJ, USA

PDB49	UNDERSTANDING AND ASSESSING THE IMPACT OF GROWTH HORMONE DEFICIENCY IN ADULTS
	Brod M¹, Meincke H², Hojby M³ ¹The BROD GROUP, Mill Valley, CA, USA, ²Novo Nordisk A/S, Bagsvarerd, Denmark, ³Novo Nordisk A/S, Bagsvaerd, Denmark

PDB50	THE COST OF DIABETES RELATED MINOR HYPOGLYCEMIC EVENTS IN WORKING ADULTS
	Brod M¹, Christensen TE², Thomsen TL², Bushnell D³ ¹The BROD GROUP, Mill Valley, CA, USA, ²Novo Nordisk A/S, Virum, Denmark, ³Health Research Associates, Inc, Mountlake Terrace, WA, USA

PDB51	USING FACTOR ANALYSIS TO CONFIRM THE VALIDITY OF DIABETES HEALTH PROFILE-1, DIABETES AND LIFE STYLE FOR TURKISH DIABETIC PATIENTS
	Malhan S¹, Oksuz E¹, Baytar S², Tulunay FC³ ¹Baskent University, Ankara, Turkey, ²Baskent University, ankara, Turkey, ³Ankara University Medical School, Ankara, Turkey

PDB52	PATIENT TREATMENT SATISFACTION OF TYPE 2 DIABETIC PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS GLARGINE OR DETEMIR AS BASAL INSULIN: RESULTS FROM THE LIVE-COM STUDY
	Moock J¹, Hessel F², Kohlmann T¹ ¹University of Greifswald, Greifswald, Germany, ²Sanofi-Aventis, Berlin, Germany

PDB53	COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES (T2DM): EFFECTS ON WORK PRODUCTIVITY.
	Purayidathil FW, Gupta S, Wagner S Consumer Health Sciences International (a KantarHealth Company), Princeton, NJ, USA

PDB54	ASSESSING THE BURDEN OF ACROMEGALY: A REVIEW OF HEALTH-RELATED QUALITY OF LIFE AND ECONOMICS
	Stephens JM¹, Gao X², Pulgar S³, Sheppard MC⁴ ¹PharMerit North America LLC, Bethesda, MD, USA, ²Pharmerit North America LLC, Bethesda, MD, USA, ³Novartis Pharmaceuticals, Florham Park, NJ, USA, ⁴The University of Birmingham, Birmingham, UK

PDB55	LINGUISTIC VALIDATION, INCLUDING CULTURAL ADAPTATION, OF AN UPDATED ADKNOWL, DIABETES KNOWLEDGE QUESTIONNAIRE, FOR INTERNATIONAL USE
	Celerier S¹, Plowright R², Reaney M³, Bradley C² ¹MAPI Institute, Lyon, France, ²University of London, Egham, UK, ³Eli Lilly, Windlesham, UK

PDB56	THE IMPACT OF STARTING INSULIN GLARGINE VERSUS INSULIN DETEMIR ON QUALITY OF LIFE (QOL) AND TREATMENT SATISFACTION (TS) IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL GLUCOSE-LOWERING DRUGS (OGLDS)
	Swinnen SG¹, Hajos T², Holleman F¹, Dain MP³, DeVries JH¹, Hoekstra JB¹, Snoek FJ² ¹Academic Medical Centre, Amsterdam, The Netherlands, ²VU University Medical Centre, Amsterdam, The Netherlands, ³Sanofi-aventis, Paris , France

PDB57	COMPARING THE IMPACT OF DEPRESSION, DIABETES, AND ANXIETY ON PATIENT PRODUCTIVITY AND QUALITY OF LIFE: RESULTS FROM A NATIONALLY REPRESENTATIVE PANEL DATA
	Bansal M¹, Nair R¹, Bollu V² ¹St. John's University, Queens, NY, USA, ²Novartis Oncology, East Hanover, NJ, USA

CANCERHealth Care Use & Policy Studies
PDB58	THE “WHO, HOW AND THEN WHAT…” OF INSULIN INITIATION IN UK PRIMARY CARE
	Smith HT¹, Blak BT², Hards M², Arellano J¹ ¹Eli Lilly and Company, Surrey, UK, ²CSD EPIC, London, UK

PDB59	USING THE ECHO MODEL TO EXAMINE THE EFFECT OF AN EMPLOYER-SPONSORED PHARMACIST PROVIDED DIABETES MTM PROGRAM ON OUTCOMES
	Pinto SL, Holl S The University of Toledo, Toledo, OH, USA

PDB60	EVALUATION OF THE PATIENT'S PERSPECTIVE OF MEDICAL CARE IN TYPE 2 DIABETES DISEASE MANAGEMENT PROGRAMS
	Stark R¹, Holle R², Schunk M³, Meisinger C³, Leidl R⁴ ¹Helmholtz Zentrum München, Neuherberg , Germany, ²Helmholtz Zentrum München, Neuherberg, Germany, ³Helmholtz Zentrum München, Neuherberg, Germany, ⁴Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg (by Munich), Germany

PDB61	DIABETES REGIMEN UTILIZATION IN A LARGE MANAGED CARE SETTING; A COMPARISON WITH ADA/EASD CONSENSUS STATEMENT GUIDELINES
	Palmer L¹, Conner C², Hammer M³, Bouchard JR⁴, Anderson JA⁵ ¹Thomson Reuters, Washington , DC, USA, ²Novo Nordisk, Seattle, WA, USA, ³Novo Nordisk A/S, Bagsværd, Denmark, ⁴Novo Nordisk, Inc., Princeton, NJ, USA, ⁵Thomson Reuters, Ann Arbor, MI, USA

PDB62	ECONOMIC IMPACT OF COMPLIANCE AND PERSISTENCE TO TREATMENT WITH ANTIDIABETES MEDICATION IN T2DM – A SYSTEMATIC REVIEW
	Breitscheidel L¹, Stamenitis S¹, Dippel FW², Schöffski O³ ¹Kendle GmbH, Munich, Germany, ²Sanofi-Aventis, Berlin, Germany, ³Universität Erlangen-Nürnberg, Nürnberg, Germany

PDB63	THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS: WAS THERE A DIFFERENTIAL EFFECT?
	Jain R¹, Mullins CD², Lee H³, Wong W³ ¹University of Georgia, Athens, , GA, USA, ²University of Maryland, Baltimore, MD, USA, ³CareFirst BlueCross BlueShield, Baltimore, MD, USA

PDB64	A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE WITH INSULIN IN PATIENTS WITH TYPE 2 DIABETES ADDING MEALTIME INSULIN TO A BASAL REGIMEN
	Kalsekar A¹, Bonafede MM², Pawaskar MD¹, McGuffie K³, Torres A⁴, Kelly KR¹, Curkendall S⁴ ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Thomson Reuters, Cambridge, MA, USA, ³Thomson Reuters, Washington, DC, USA, ⁴Thomson Reuters, Washington DC , DC, USA

PDB65	REAL-LIFE PRESCRIPTION PATTERNS SHOW FEWER TREATMENT CHANGES WITH BASAL INSULIN ANALOGS COMPARED TO NPH IN TYPE 2 DIABETES IN THE NETHERLANDS
	Thomsen TL¹, Heintjes EM², Penning-van Beest FJ², Christensen TE¹, Herings RM² ¹Novo Nordisk A/S, Virum, Denmark, ²PHARMO Institute, Utrecht, The Netherlands

PDB66	PAYING FOR COSTLY PHARMACEUTICALS - REIMBURSEMENT STATUS OF LONG-ACTING INSULIN ANALOGUES IN SELECTED DEVELOPED COUNTRIES
	Orlewska E¹, Gulácsi L² ¹Centrum Farmakoekonomiki, Warsaw, Poland, ²Corvinus University of Budapest, Budapest, Hungary

PDB67	HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC
	Tesar T, Foltan V, Binder R Comenius University, Bratislava, Slovak Republic

PDB68	A RETROSPECTIVE ANALYSIS OF MEDICATION USE, RESOURCE UTILIZATION, AND CLINICAL EFFECTIVENESS OF EXENATIDE COMPARED TO GLARGINE IN PATIENTS WITH TYPE 2 DIABETES
	Pawaskar MD¹, Anderson J¹, Zagar AJ² ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Lilly USA, LLC, Indianapolis, IN, USA

PDB69	SIGNIFICANT REDUCTIONS IN POLYPHARMACY AND HEALTH CARE UTILIZATION WITH INSULIN PUMP THERAPY (CSII) IN PATIENTS WITH TYPE 2 DIABETES
	Lynch P¹, Riedel AA², Fan Y², Samant ND², Levinson J¹, Lee SW¹ ¹Medtronic Diabetes, Northridge, CA, USA, ²i3 Innovus, An Ingenix Company, Eden Prairie, MN, USA

PDB70	ORAL MEDICATIONS VS INSULIN FOR DIABETES:EPIDEMIOLOGICAL & HEALTH POLICY IMPLICATIONS IN GREECE
	Hatzikou M, Koumi O, Andreadaki E, Rombopoulos G, Roubou I, Jovicevic B Novartis Hellas, Metamorphosis, Greece

PDB71	GLYCAEMIC AND CHOLESTEROL CONTROL OF TYPE 2 DIABETIC PATIENTS ATTENDING SPECIALIST OUTPATIENT CLINICS IN SINGAPORE
	Lim BK¹, Toh MPHS¹, Cheah TSJ¹, Sum Chee F², Jong M³, Chionh SB⁴ ¹National Healthcare Group, Singapore, Singapore, ²Alexandra Hospital, Singapore, Singapore, ³Tan Tock Seng Hospital, Singapore, Singapore, ⁴National University Hospital, Singapore, Singapore

PDB72	QUALITY ADJUSTED LIFE YEARS LOSS DUE TO TYPE 2 DIABETES IN SOUTH KOREA
	Jo MW¹, Lee WJ¹, Noh JH², Choi Y³, Song KH⁴ ¹University of Ulsan, Seoul, South Korea, ²Inje University Ilsan Paik Hospital, Ilsan, Gyeonggi-Do, South Korea, ³sanofi-aventis Korea, Seoul, South Korea, ⁴Kunkuk University Hospital, Seoul, South Korea

PDB73	ANALYSIS OF FACTORS INFLUENCING DECISION MAKING ON TYPE 2 DIABETES DRUGS IN 5 HTA-AGENCIES
	Adalsteinsson E¹, Jensen RCØ², Mondher T³, Hemels M⁴ ¹Novo Nordisk, Soeborg, Denmark, ²Novo Nordisk A/S, Bagsværd, Denmark, ³University Claude Bernard Lyon, Lyon, France, ⁴Novo Nordisk A/S, bagsværd, Denmark

PDB74	ETHICAL DILEMMAS OF PHARMACOLOGICAL TREATMENT AND SELF MANAGEMENT OF DIABETES – A REVIEW OF THE LITERATURE
	Jensen RCØ¹, Kaas C², Mondher T³, Hemels M⁴ ¹Novo Nordisk A/S, Bagsværd, Denmark, ²Copenhagen University, Copenhagen, Denmark, ³University Claude Bernard Lyon, Lyon, France, ⁴Novo Nordisk A/S, bagsværd, Denmark

PDB75	APPLICATION OF HTA TO ANTIDIABETIC DRUG FORMULARY DECISIONS
	Andreykiv M, Wiebinga C Quintiles Consulting, Hoofddorp, The Netherlands

PDB76	ETHICAL ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS OF DIABETES TREATMENTS
	Kaas C¹, Jensen RCØ², Adalsteinsson E³ ¹Copenhagen University, Copenhagen, Denmark, ²Novo Nordisk A/S, Bagsværd, Denmark, ³Novo Nordisk A/S, Soeborg, Denmark

PDB77	BASELINE CHARACTERISTICS OF PATIENTS BEGINNING BASAL, BASAL PLUS SHORT-ACTING, SHORT-ACTING OR PREMIX INSULIN: DATA FROM THE CREDIT STUDY
	Home P¹, Blonde L², Marre M³, Admane K⁴, Vespasiani G⁵ ¹Newcastle University, Newcastle upon Tyne, UK, ²Ochsner Medical Center, New Orleans, LA, USA, ³Université Paris, INSERM U695, Paris, France, ⁴Sanofi-Aventis, Paris, France, ⁵Diabetology and Metabolic Disorders Centre, Ascoli Piceno, San Benedetto del Tronto, Italy

PDB78	DIFFERENCES IN THE CHARACTERISTICS OF PEOPLE WITH TYPE 2 DIABETES STARTING INSULIN IN THE NORTH, SOUTH AND EAST OF EUROPE: DATA FROM THE CREDIT STUDY
	Marre M¹, Home P², Vespasiani G³, Admane K⁴, Blonde L⁵ ¹Université Paris, INSERM U695, Paris, France, ²University of Newcastle upon Tyne, Newcastle upon Tyne, UK, ³Diabetology and Metabolic Disorders Centre, Ascoli Piceno, San Benedetto del Tronto, Italy, ⁴Sanofi-Aventis, Paris, France, ⁵Ochsner Medical Center, New Orleans, LA, USA

PDB79	DO PEOPLE BEGINNING BASAL INSULIN HAVE A DISTINCT CLINICAL PROFILE COMPARED WITH THE OVERALL POPULATION IN THE CREDIT STUDY?
	Vespasiani G¹, Marre M², Blonde L³, Admane K⁴, Home P⁵ ¹Diabetology and Metabolic Disorders Centre, Ascoli Piceno, San Benedetto del Tronto, Italy, ²Université Paris, INSERM U695, Paris, France, ³Ochsner Medical Center, New Orleans, LA, USA, ⁴Sanofi-Aventis, Paris, France, ⁵University of Newcastle upon Tyne, Newcastle upon Tyne, UK

PDB80	WITHDRAWN

PDB81	THE ROAD TO INSULIN - A PATH OF TREATMENT ANALYSIS OF REAL-WORLD PHARMACY DATA FROM THE USA
	Christensen TE¹, Thomsen TL¹, Bouchard JR², Seligman R³, Hamlin D³ ¹Novo Nordisk A/S, Virum, Denmark, ²Novo Nordisk, Inc., Princeton, NJ, USA, ³SDI Health, Boston, NY, USA

POSTER PRESENTATIONS SESSION III
SET-UP:	Tuesday, 27 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Tuesday, 27 October, 8:00 – 16:00
POSTER AUTHOR DISCUSSION HOUR:	Tuesday, 27 October, 11:00 – 12:00
DISMANTLE:	Tuesday, 27 October, 16:00 – 16:30

INFECTION Clinical Outcomes Studies
PIN1	FRENCH OBSERVATIONAL COHORT OF HIV-1 INFECTED PATIENTS TREATED WITH ENFUVIRTIDE : LONG-TERM EFFICACY AND SAFETY (ZOOM)
	Meynard JL¹, Morand-Joubert L¹, Chene G², Landman R³, Obadia M⁴, Castrec E⁵, Barbaza MO⁶, Vivier G⁷, Rose S⁵, Moser A⁵, Pinta A⁵, Kraemer S⁸, Girard PM¹ ¹Hôpital Saint-Antoine, Paris, France, ²Groupe hospitalier Pellegrin, Bordeaux, France, ³Hôpital Bichat Claude Bernard, Paris , France, ⁴Hôpital Purpan, Toulouse, France, ⁵Roche, Neuilly sur seine, France, ⁶Auxesia, Decines Charpieu, France, ⁷DOC'S international, Issy les Moulineaux, France, ⁸Lincoln, Boulogne Billancourt, France

PIN2	HCV INFECTION IS ASSOCIATED WITH HIGH COMORBIDITY BURDEN IN EUROPE
	Zhang HF¹, Mills DL², Wagner S², Freedman D² ¹Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA, ²Consumer Health Sciences International, Princeton, NJ, USA

PIN3	PREDICTORS OF EFFECTIVENESS WITH LOPINAVIR/RITONAVIR (LPV/R) SINGLE AGENT THERAPY (SAT) TO IMPROVE CLINICAL OUTCOMES IN HIGH RISK HIV+ PATIENTS IN AN URBAN CLINIC
	Yeh RF¹, Wattal R¹, Sansgiry SS¹, Sudharshan L¹, Yost S¹, Mayberry C², Ceperley M¹, Rahim S³, Gathe JC² ¹University of Houston, Houston, TX, USA, ²Therapeutic Concepts, P.A., Houston, TX, USA, ³Abbott Laboratories, Abbott Park, IL, USA

PIN4	SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF EXTERNAL GENITAL WARTS
	Walczak J, Nogas G, Chmiel M, Kowalska M Arcana Institute, Cracow, Poland

PIN5	UNDERESTIMATION OF VARICELLA INCIDENCE IN THE NETHERLANDS
	Pierik JGJ¹, Gumbs PD², Fortanier AC², Van Steenwijk PCE³, Postma MJ¹ ¹University of Groningen, Groningen, The Netherlands, ²GlaxoSmithKline BV, Zeist, The Netherlands, ³Zorggroep Almere, Almere, The Netherlands

PIN6	OUTCOME AND RESOURCES USE OF SEVERE BURN INJURY PATIENTS WITH NOSOCOMIAL BLOODSTREAM INFECTION: RESULTS OF A MATCHED COHORT STUDY
	Brusselaers N¹, Monstrey S¹, Hoste E¹, Lizy C¹, Vandijck D², Vandekerckhove L¹, Annemans L², Vogelaers D¹, Blot S¹ ¹Ghent University Hospital, Ghent, Belgium, ²Ghent University, Ghent, Belgium

INFECTIONCost Studies
PIN7	BUDGETARY IMPACT OF ADDING DORIPENEM TO A HOSPITAL FORMULARY IN GERMANY
	Kongnakorn T¹, De Cock E², Kubitz N³, Merchant S⁴, Schreder H³ ¹United BioSource Corporation, Lexington, MA, USA, ²United BioSource Corporation, Barcelona, Spain, ³Janssen-Cilag GmbH, Neuss, Germany, ⁴Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA

PIN8	BUDGET-IMPACT ANALYSIS OF ADDING THE NEW 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION (PHID-CV) TO ROUTINE INFANT VACCINATION IN CANADA
	Ismaila AS¹, Pereira JA¹, Robson RC¹, Talbird SE², Standaert BA³, Rawson NS¹ ¹GlaxoSmithKline, Mississauga, ON, Canada, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³GlaxoSmithKline Biologicals, Rixensart, Belgium

PIN9	THE COST OF PREVENTING INFLUENZA PANDEMIC: MEXICAN ELDERLY POPULATION SCENARIO
	Soria-Cedillo IF¹, Baca-Muro VI², Alejandro P³, Garcia-Contreras F⁴ ¹Research Consulting, Hacienda Ojo de Agua, Mexico, ²Research Consulting, Puebla, Mexico, ³Novartis Farmaceutica Mexico, Mexico City, Mexico City, Mexico, ⁴Instituto Mexicano de Seguro Social, Mexico D.F., Mexico

PIN10	A BUDGET IMPACT MODEL TO ESTIMATE THE ECONOMIC IMPACT OF ITRACONAZOLE IN PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH NEUTROPENIA IN SPAIN
	Darba J¹, Restovic G² ¹Universitat de Barcelona, Barcelona, Spain, ²BCN Health Economics & Outcomes Research SL, Barcelona, Spain

PIN11	BUDGET IMPACT ANALYSIS OF NEW ANTRIRETROVIRAL MEDICINES FOR TREATMENT OF HIV PATIENTS IN BULGARIA
	Dimitrova MJ, Stefanova MT, Petrova GI Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria

PIN12	BUDGET IMPACT ANALYSIS OF THREE CANDINS IN THE TREATMENT OF INVASIVE CANDIDIASIS IN ADULT NON- NEUTROPENIC PATIENTS IN SPAIN
	García M, Martí B, Ferro B Health Outcomes Research, Pfizer, Spain

PIN13	BUDGET IMPACT MODEL: LEVOFLOXACIN VS STANDARD THERAPIES IN THE TREATMENT OF INPATIENT CAP
	Pitrelli A¹, Bamfi F¹, Pippo L² ¹GlaxoSmithKline Spa, Verona, Italy, ²GlaxoSmithKline Verona -Italy, Verona, Italy

PIN14	BUDGET IMPACT OF HIV POST-EXPOSURE PROPHYLAXIS: AN EXAMPLE OF HOSPITAL POINT OF VIEW AFTER NEW RECOMMENDATIONS IN FRANCE
	Bernard M, Askin D, Massias L, Arnaud P Bichat-Claude Bernard hospital, Paris, Ile de france, France

PIN15	THE ECONOMIC IMPLICATION OF A RAPID DIAGNOSE AND EARLY SHIFT IN THERAPY IN PATIENTS WITH INVASIVE CANDIDA INFECTION
	Kolbye A¹, Clausen SR¹, Schierbeck J², Andersen JS³ ¹Pfizer Denmark, Ballerup, Denmark, ²Odense University Hospital, Odense C, Denmark, ³Copenhagen University Hospital, Copenhagen E, Denmark

PIN16	COST-EFFECTIVENESS OF HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-7) IN MEXICO
	Carlos F¹, Mercado G², Aguirre A², Vargas A¹, Bierschwale H² ¹R A C Salud Consultores, SA de CV, Ciudad de Mexico, Distrito Federal, Mexico, ²Wyeth México, Naucalpan, Mexico

PIN17	THE COST OF ROTAVIRUS GASTROENTERITIS IN YOUNG CHILDREN IN FOUR EUROPEAN COUNTRIES: A STUDY IN PRIMARY CARE
	Curran D¹, Giaquinto C², Diez-Domingo J³, Patrzalek M⁴, Pazdiora P⁵, Rosillon D⁶ ¹Omega Research, Dublin 9, Ireland, ²University of Padova, Padova, Veneto, Italy, ³C.S.I.S.P. (Center for Public Health Research)., Valencia, Spain, ⁴25-339 Kielce ul.Zagórska, Kielce, Poland, ⁵Charles University Pilsen, Pilsen, Czech Republic, ⁶GSK, Rixensart, Belgium

PIN18	THE COST BURDEN OF ACUTE GASTROENTERITIS IN INFANTS AND YOUNG CHILDREN ATTENDING DAYCARE CENTRES IN FRANCE
	Curran D¹, Grimpel E², Meyer N³, Pircon JY³ ¹Omega Research, Dublin 9, Ireland, ²Hopital Trousseau, Paris, France, ³GSK, Rixensart, Belgium

PIN19	TREATMENT COSTS FOR CHRONIC HEPATITIS B (CHB) IN URBAN CHINA
	Wang Z¹, Xiong X², He M³, Dong Z¹, He P¹ ¹National Institute of Social Security Studies, Ministry of Human Resource and Social Security, PRC, Beijing, Beijing, China, ²China Health Insurance Research Association, Beijing, Beijing, China, ³School of Management,Beijing Traditional Medicine University, Beijing, Beijing, China

PIN20	BURDEN OF PEDIATRIC INFLUENZA IN EUROPE: A GAP ANALYSIS
	Rycroft C¹, Beard S¹, Leeuwenkamp O², Moren S³ ¹RTI Health Solutions, Manchester, UK, ²MedImmune, Cambridge, Cambridgeshire, UK, ³MedImmune LLC, Gaithersburg, MD, USA

PIN21	BURDEN AND COST OF SNAKEBITE ENVENOMING: ANTIVENOM OUT OF REACH?
	Aggarwal A, Pathak P, Thakur D Heron Health Private Ltd, Chandigarh, India

PIN22	ANNUAL COSTS OF CHRONIC HEPATITIS B DISEASE STATES IN PORTUGAL
	Raluy M¹, De Cock E¹, Marinho RT², Areias J³, Calinas F⁴, Carvalho A⁵, Matos L⁶, Rodrigues B⁷, Macedo G⁸, Velosa J², Perelman J⁹ ¹United BioSource Corporation, Barcelona, Spain, ²Hospital Santa Maria, Lisbon, Portugal, ³Hospital de Santo António, Porto, Portugal, ⁴Hospital Santo António dos Capuchos, Lisbon, Portugal, ⁵Hospitais da Universidade de Coimbra, Coimbra, Portugal, ⁶Hospital Egas Moniz, Lisbon, Portugal, ⁷Hospital Pulido Valente, Lisbon, Portugal, ⁸Hospital de S. Marcos, Braga, Portugal, ⁹Escola Nacional de Saúde Pública, Lisbon, Portugal

PIN23	POOR ADHERENCE TO TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION IS ASSOCIATED WITH GREATER HEALTH CARE COSTS
	Baran RW¹, Bhor M², Laitinen D², Dietz B³ ¹Abbott Laboratories, Inc, Abbott Park, IL, USA, ²Abbott Laboratories, Abbott Park, IL, USA, ³Abbott GmbH & Co., Ludwigshafen, Germany

PIN24	DIFFERENT APPROACHES FOR ESTIMATING INDIRECT COST IN THE ECONOMIC ASSESSMENT OF PNEUMOCOCCAL VACCINES IN GERMANY
	Jochum D, Knoll S GlaxoSmithKline GmbH & Co. KG, Munich, Bavaria, Germany

PIN25	WITHDRAWN


PIN26	CLINICAL AND ECONOMIC IMPACTS OF BACTEREMIA CAUSED BY EXTENDED-SPECTRUM BETA–LACTAMASES PRODUCING ESCHERICHIA COLI IN HONG KONG
	Mok SS, Chang CC, Ip M, You JH The Chinese University of Hong Kong, Shatin, N.T, Hong Kong

PIN27	COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN AND TEICOPLANIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS IN CZECH REPUBLIC
	Suchankova E¹, Dolezal T², Hájek P³, Kovár P³ ¹Charles University, Prague , Czech Republic, ²Charles University, Praha, Czech Republic, ³Pfizer, Praha 5, Czech Republic

PIN28	ECONOMIC ANALYSIS ABOUT VALGANCICLOVIR PROPHYLAXIS AGAINST INFECTION FROM CITOMEGALOVIRUS IN PATIENTS WITH RENAL TRANSPLANTATION
	García-Tellez I¹, Alberú J², Sierra-Madero J³ ¹Roche México, Mexico D.F, Mexico, ²National Institute of Medical Sciences and Nutrition, México D.F., Mexico, ³National Institute of Medical Sciences and Nutrition, Mexico D.F., Mexico

PIN29	COST OF DIABETIC FOOT INFECTIONS DUE TO MRSA: AN ECONOMIC ANALYSIS OF DATA FROM PATIENTS TREATED WITH LINEZOLID IN SPAIN
	Zaragoza R¹, García M², Blanes L³, Flores J⁴, Chacón A⁵, Hernández F⁶, Escudero E² ¹Servicio de Medicina Intensiva, Hospital Universitario Dr. Peset, Valencia, Spain, ²Pfizer, Madrid, Spain, ³Servicio de Angiología y Cirugía Vascular. Hospital Universitario Dr. Peset, Valencia, Spain, ⁴Servicio Medicina Interna-UEI. Hospital Universitari Arnau de Vilanova, Valencia, Spain, ⁵Servicio de Cirugía Cardiovascular. Hospital Reina Sofía, Córdoba, Spain, ⁶Biometrics, Euroclin Institute, Barcelona, Spain

PIN30	USE OF NET-BENEFIT REGRESSION FRAMEWORK TO INVESTIGATE THE COST-EFFECTIVENESS OF COMBINATION ANTIVIRAL THERAPY AMONG HCV-INFECTED PATIENTS ENROLLED IN A MANAGED CARE ORGANIZATION
	Hsu CN, Kauf TL University of Florida, Gainesville, FL, USA

PIN31	COST-EFFECTIVENESS ANALYSIS OF TELBIVUDINE VS LAMIVUDINE IN TREATING THE PATIENTS WITH HBEAG-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B IN CHINA
	Chen W¹, Hou J² ¹Fudan University, Shanghai, China, ²Southern Medical University, Guangzhou, China

PIN32	COST EFFECTIVENESS OF UNIVERSAL ROTAVIRUS VACCINATION IN IRELAND: A PRELIMINARY ANALYSIS
	Redmond S¹, Standaert B² ¹GlaxoSmithKline, Dublin 16, Ireland, ²GlaxoSmithKline Biologicals, Rixensart, Belgium

PIN33	POTENTIAL HEALTH AND ECONOMIC IMPACT OF NEW PNEUMOCOCCAL VACCINES IN CANADA: A MARKOV MODELLING APPROACH
	Ismaila AS¹, Chen YC², Standaert BA², Pereira JA¹, Robson RC¹ ¹GlaxoSmithKline, Mississauga, ON, Canada, ²GlaxoSmithKline Biologicals, Rixensart, Belgium

PIN34	ECONOMIC ASSESSMENT OF MASS VACCINATION WITH PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE (PHID-CV) IN POLAND
	Kawalec P¹, Holko P², Dziurda D³, Glogowski C⁴ ¹Centrum HTA, Krakow, Poland, ²Centrum HTA, Krakow , Poland, ³GlaxoSmithKline Commercial Sp z o.o., Warsaw, Poland, ⁴GSK Commercial Sp. z o.o, Warsaw, Poland

PIN35	CLINICAL AND ECONOMIC BENEFITS OF NATIONAL IMMUNIZATION WITH THE 13-VALENT COMPARED TO 7- AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN GREECE
	Papanicolaou S¹, Kontodimas S², Syriopoulou V³, Tsolia M⁴, Theodoridou M⁴, Strutton DR⁵, Hwang S⁵, Tzanakaki G⁶, Kremastinou J⁶, Earnshaw SR⁷, Farkouh R⁷, Karokis A⁸, Konstantopoulos A³ ¹PRMA Consulting Ltd, Hampshire, UK, ²Wyeth Hellas S.A, Athens, Attika, Greece, ³University of Athens, Athens, Greece, ⁴University of Athens School of Medicine, Athens , Greece, ⁵Wyeth Research, Collegeville, PA, USA, ⁶National School of Public Health, Athens, Greece, ⁷RTI Health Solutions, Research Triangle Park, NC, USA, ⁸Wyeth, Athens, Greece

PIN36	WITHDRAWN


PIN37	COST EFFECTIVENESS OF PEGYLATED-INTERFERON ALPHA 2B + RIBAVIRIN FOR CHRONIC HEPATIITIS C (CHC) IN PATIENTS WHO HAVE PREVIOUSLY FAILED TREATMENT WITH INTERFERON- BASED THERAPY IN AUSTRALIA
	Norris S¹, Campbell S¹, Radalj L¹, Elliott L¹, Dunlop SL² ¹Health Technology Analysts Pty Ltd, Balmain, NSW, Australia, ²Schering Plough Pty Limited, North Ryde, NSW, Australia

PIN38	COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB IN THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN CHILDREN WITH CONGENITAL HEART DISEASE
	Kang HY¹, Kim HS¹, Choi JY¹, Kim YH² ¹Yonsei University, Seoul, South Korea, ²University of Ulsan, Seoul, South Korea

PIN39	COST-EFFECTIVENESS OF MASS VARICELLA VACCINATION IN FRANCE: ECONOMIC CONSEQUENCES OF AN INTENSIVE VACCINATION PROGRAM
	Littlewood KJ¹, Sauboin C², Ouwens M³ ¹Mapi Values, Houten, The Netherlands, ²GlaxoSmithKline Biologicals, Rixensart, Belgium, ³Mapi Values Netherlands B.V., Houten, The Netherlands

PIN40	COST-EFFECTIVENESS OF DORIPENEM IN THE TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN MEXICO
	Soto-Molina H, Celaya JM, Hernandez Guerrero N, Castillejos C Janssen Cilag, Mexico, Mexico

PIN41	PREVENTION OF AN INFLUENZA PANDEMIC IN MEXICO: ESTABLISHING A COST-EFFECTIVE ALTERNATIVE FOR ELDERLY POPULATION
	Baca-Muro VI¹, Soria-Cedillo IF², Olvera K³, Garcia-Contreras F⁴ ¹Research Consulting, Puebla, Mexico, ²Research Consulting, Hacienda Ojo de Agua, Mexico, ³Novartis Farmaceutica México, Mexico D.F., Mexico, ⁴Instituto Mexicano de Seguro Social, Mexico D.F., Mexico

PIN42	COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENT TO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
	Claes C¹, Mittendorf T¹, Kuchenbecker U², Rose M³, Reinert RR⁴ ¹Leibniz University of Hannover, Hannover, Germany, ²Wyeth Pharma, Muenster, Germany, ³Johann Wolfgang Goethe University Frankfurt a.M., Frankfurt a.M., Germany, ⁴Wyeth Vaccines Research, Paris la Defense, France

PIN43	COST-EFFECTIVENESS OF 13-VALENT AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION RELATIVE TO 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA
	Whillans F¹, Kwan H¹, Strutton DR², Earnshaw SR³, Farkouh R³ ¹Wyeth Pharmaceuticals, Markham, ON, Canada, ²Wyeth Research, Collegeville, PA, USA, ³RTI Health Solutions, Research Triangle Park, NC, USA

PIN44	A COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN FOR TREATMENT OF SYSTEMIC CANDIDA INFECTIONS IN ITALY
	Sidhu MK¹, Van Engen AK², Switjnk AB², Concia E³ ¹Astellas Pharma Europe Ltd, Staines, UK, ²Quintiles Consulting, Hoofddorp, The Netherlands, ³University of Verona, Verona, Italy

PIN45	COST-EFFECTIVENESS OF A COCOONING IMMUNIZATION STRATEGY AGAINST PERTUSSIS FOR THE NETHERLANDS
	Westra TA¹, de Vries R², Tamminga HJ³, Wilschut JC⁴, Sauboin C⁵, Postma MJ² ¹University Medical Centre Groningen, Groningen, The Netherlands, ²University of Groningen, Groningen, The Netherlands, ³GlaxoSmithKline, Zeist, The Netherlands, ⁴University Medical Center Groningen, Groningen, The Netherlands, ⁵GlaxoSmithKline Biologicals, Rixensart, Belgium

PIN46	COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS PODOPHYLLOTOXIN IN TREATMENT OF GENITAL/PERIANAL WARTS IN POLAND
	Walczak J, Nogas G, Dybek-Karpiuk A, Kloc K, Labak M, Pawlik D Arcana Institute, Cracow, Poland

PIN47	MODELING THE OUTCOMES OF VACCINATION WITH THE 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN SPAIN
	Marès J¹, Moraga-Llop F², Fenoll A³, Pérez-Alcántara F⁴, Pérez I⁵, Morano R⁵ ¹Institut Pediàtric Marès-Riera, Blanes, Girona, Spain, ²Paediatrician, Barcelona, Spain, ³Spanish Reference Laboratory for Pneumococci, Insituto Carlos III, Madrid, Spain, ⁴Oblikue Consulting S.L., Barcelona, Spain, ⁵GlaxoSmithKline, Madrid, Spain

PIN48	COMPARATIVE COST-EFFICACY ANALYSIS OF DARUNAVIR/R AND OTHER RITONAVIR-BOOSTED PROTEASE INHIBITORS FOR FIRST-LINE TREATMENT OF HIV-1 INFECTION IN GERMANY
	Brogan A¹, Soorapanth S¹, Donatz V², Hill A³, Smets E⁴ ¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Tibotec, Division of Janssen-Cilag GmbH, Neuss, Germany, ³Pharmacology Research laboratories, University of Liverpool, Liverpool, UK, ⁴Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium

PIN49	A PHARMACOECONOMIC EVALUATION OF INFLUENZA VACCINATION IN THE ELDERLY POPULATION IN ITALY
	Iannazzo S, Sacchi V AdRes HE&OR, Torino, Italy

PIN50	MICAFUNGIN VS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR GERMANY
	Felder S¹, Grabe K², Mayrhofer T¹, Decker S¹ ¹Duisburg-Essen University, Essen, Germany, ²Astellas Pharma GmbH, Munich, Germany

PIN51	COST-EFFECTIVENESS STUDY OF THE USE OF DAPTOMYCIN VERSUS VANCOMYCIN IN INFECTIVE ENDOCARDITIS AND BACTEREMIA TREATMENT IN PUBLIC HEALTH INSTITUTIONS IN MEXICO
	Soria-Cedillo IF¹, Baca-Muro VI², De la Mora-Chávez T³, Jirash J⁴, Garcia-Contreras F⁵ ¹Research Consulting, Hacienda Ojo de Agua, Mexico, ²Research Consulting, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁴Novartis Farmaceutica Mexico, Mexico D>F., Mexico, ⁵Instituto Mexicano de Seguro Social, Mexico D.F., Mexico

PIN52	COST ESTIMATES IN THE ECONOMIC EVALUATIONS OF VACCINATION PROGRAMMES: THE CASES OF ROTAVIRUS AND VARICELLA IN BRAZIL
	Valentim J, Sartori A, Amaku M, Soarez P, Azevedo R, Novaes H University of São Paulo, São Paulo, SP, Brazil

PIN53	COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE 1 (G1) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE
	Jensen DM¹, Marcellin P², Urspruch A³, Papadakis K⁴, Tonev D⁴ ¹University of Chicago Medical Center, Chicago, IL, USA, ²Hôpital Beaujon, Clichy, France, ³F. Hoffmann La Roche Ltd., Basel, Switzerland, ⁴Roche Products Ltd., Welwyn Garden City, UK

PIN54	THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCV13) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK
	Patel R¹, Stoykova B², Lloyd AC¹, Willingham J², Hollingsworth R² ¹IMS Health, London, UK, ²Wyeth, Maidenhead, Berkshire, UK

PIN55	COST-EFFECTIVENESS OF THE SURVIVING SEPSIS CAMPAIGN PROTOCOL FOR SEVERE SEPSIS IN SPAIN
	Suarez D¹, Ferrer R², Artigas A², Garnacho-Montero J³, Levy MM⁴ ¹Fundacio Parc Tauli Institut Universitari, Universitat Autonoma de Barcelona, Sabadell , Barcelona, Spain, ²Hospital de Sabadell. CIBER Enfermedades Respiratorias. Instituto Universitario Parc Tauli, UAB, Sabadell , Barcelona, Spain, ³Hospital Universitario Virgen del Rocio, Sevilla, Sevilla, Spain, ⁴Brown University, School of Medicine, Providence, Rhode Island, Providence, RI, USA

PIN56	COST–EFFECTIVENESS OF ATAZANAVIR/R VS. LOPINAVIR/R IN TREATMENT NAIVE HIV PATIENTS IN SPAIN
	Thuresson PO¹, Heeg B¹, Serrano O², Ramirez de Arellano A² ¹PharMerit Europe, Rotterdam, The Netherlands, ²Bristol-Myers Squibb Iberia, Madrid, Spain

PIN57	A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
	Patel R¹, Stoykova B², Lloyd AC¹, Willingham J², Hollingsworth R² ¹IMS Health, London, UK, ²Wyeth, Maidenhead, Berkshire, UK

PIN58	COST-EFFECTIVENESS OF ETRAVIRINE IN SWEDEN IN TREATMENT-EXPERIENCED HIV-1-INFECTED ADULTS WITH EVIDENCE OF NNRTI RESISTANCE AND AT LEAST 3 PI MUTATIONS
	Moeremans K¹, Hjelmgren J², Martin SC³ ¹IMS HEOR, Brussels, Belgium, ²Janssen-Cilag AB, Sollentuna, Sweden, ³Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium

PIN59	POTENTIAL ECONOMIC IMPACT OF OUTPATIENT CARBAPENEM TREATMENT FOR BACTERAEMIA CAUSED BY ESBL-PRODUCING BACTERIA IN HONG KONG – A DECISION ANALYSIS
	You JH, So M, So Y, Ip M, Lee NL The Chinese University of Hong Kong, Shatin, N.T, Hong Kong

PIN60	COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A VERSUS ENTECAVIR IN THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA
	Sheng F Shanghai Roche Pharmaceuticals Ltd, Shanghai, Shanghai, China

PIN61	COST-UTILITY ANALYSIS OF ROTAVIRUS VACCINE (ROTARIX®) IN JAPAN
	Igarashi A¹, Fukuda T¹, Orihara S¹, Suzuki H², Tsutani K¹ ¹University of Tokyo, Bunkyo, Tokyo, Japan, ²Niigata University, Niigata, Niigata, Japan

PIN62	COST-EFFECTIVENESS OF TARGETED SCREENING FOR HEPATITIS C IN THE NETHERLANDS
	Helsper CW¹, Borkent-Raven BA¹, de Wit NJ¹, van Essen GA¹, Bonten M², Janssen MP¹, Hoepelman I¹, De Wit GA³ ¹UMC Utrecht, Utrecht, The Netherlands, ²Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands, ³National Institute for Public Health and the Environment, Bilthoven, The Netherlands

PIN63	COST-UTILITY ANALYSIS OF PNEUMOCOCCAL CONJUGATE VACCINES IN GERMANY
	Knoll S¹, Jochum D¹, Talbird SE² ¹GlaxoSmithKline GmbH & Co. KG, Munich, Bavaria, Germany, ²RTI Health Solutions, Research Triangle Park, NC, USA

PIN64	A PROBABILISTIC COST-EFFECTIVENESS MODEL FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH NEUTROPENIA IN SPAIN
	Darba J¹, Restovic G² ¹Universitat de Barcelona, Barcelona, Spain, ²BCN Health Economics & Outcomes Research SL, Barcelona, Spain

PIN65	IMPACT OF ETRAVIRINE (ETR) ON HOSPITALISATIONS AND HOSPITAL-RELATED COSTS CALCULATED BY GERMAN-DRGS: 48-WEEK FINDINGS FROM POOLED DUET TRIALS
	Stoll M¹, Donatz V², Corbett CJ³, Martin SC⁴ ¹Medical School Hannover, Hannover, Germany, ²Tibotec, Division of Janssen-Cilag GmbH, Neuss, Germany, ³Tibotec-Virco, Mechelen, Belgium, ⁴Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ, USA

INFECTION Patient-Reported Outcomes Studies
PIN66	SPILLOVER ADHERENCE EFFECTS OF FIXED-DOSE COMBINATION HIV THERAPY
	Kauf TL¹, Davis KL², Earnshaw SR², Davis EA³, Watson ME³ ¹University of Florida, Gainesville, FL, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³GlaxoSmithKline, Research Triangle Park, NC, USA

PIN67	QUALITY OF LIFE AND HEALTH CARE UTILIZATION BURDEN OF HCV-INFECTED PATIENTS IN EUROPE
	Zhang HF¹, Mills DL², Wagner S², Freedman D² ¹Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA, ²Consumer Health Sciences International, Princeton, NJ, USA

PIN68	PSYCHOMETRIC EVALUATION OF THE FUNCTIONAL ASSESSMENT OF HIV INFECTION (FAHI) QUESTIONNAIRE IN TWO CLINICAL PROGRAMMES
	Gilet H¹, Martin SC², Viala M¹ ¹Mapi Values France, Lyon, France, ²Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ, USA

PIN69	WITHDRAWN


PIN70	PERCEPTION AND ACCEPTANCE OF INTRADERMAL INFLUENZA VACCINE MEASURED BY THE VACCINEE'S PERCEPTION OF INJECTION (VAPI©) QUESTIONNAIRE
	Meunier J¹, Reygrobellet C², Weber F², Nguyen VH³, Viala-Danten M⁴ ¹Mapi Values, Lyon, France, ²Sanofi pasteur, Lyon, France, ³Sanofi Pasteur, Lyon, France, ⁴Mapi Values France, Lyon, France

PIN71	QUALITY OF LIFE (QOL) AND OTHER ENDPOINTS COMPARISON IN THE TREATMENT OF FACIAL LIPOATROPHY WITH INJECTION OF POLY-L-LACTIC ACID
	Duracinsky M¹, Dolivo M², Beaulieu P³, Timsit J², Secchi T⁴, Mouly F⁵, Lalanne B⁶, Leclerc P⁷, Chassany O⁸ ¹Centre Hospitalier Universitaire de Bicetre, Le Kremlin-Bicetre, France, ²Hop St Louis, paris, France, ³Dermatologue, Pontoise , France, ⁴Dermatologue, Lyon, France, ⁵Dermatologue, paris, France, ⁶Chirurgien Plasticien, paris, France, ⁷CHU Grenoble, Grenoble, France, ⁸Assistance Publique - Hopitaux de Paris, Paris, France

PIN72	TRANSLATION OF THE HIV PATIENT SYMPTOMS PROFILE INTO 5 LANGUAGES SPOKEN IN ISRAEL
	Brunel V, Salmassi L MAPI Institute, Lyon, France

INFECTION Health Care Use & Policy Studies
PIN73	CRITICAL CARE ADMISSIONS FOR PNEUMONIA IN ENGLAND
	Das R AstraZeneca UK Ltd, Luton, UK

PIN74	LEAST COSTLY VACCINATION STRATEGY (WITH OR WITHOUT SCREENING FOR ANTOBODIES) FOR HEPATITIS A, HEPATITIS B, VARICELLA, MEASLES AND TETANUS IN CATALONIA, SPAIN
	Plans-Rubió P¹, Huang H² ¹General Directorate of Public Health, Barcelona, Spain, ²Boston Health Economics, Waltham, MA, USA

PIN75	ECONOMIC IMPACT OF NEW MALARIA DIAGNOSTIC DEVICES ON THE MALARIA CONTROL PROGRAM IN BRAZIL
	Quinn BP¹, Hummel JM¹, Laubscher M², IJzerman MJ¹ ¹University of Twente, Enschede, The Netherlands, ²Philips Research, Eindhoven, The Netherlands

PIN76	THE PREVALENCE, MORTALITY, AND COST OF CENTRAL LINE BLOOD STREAM INFECTIONS (CLABSI) IN US COMMUNITY HOSPITALS: 2002 TO 2006
	Dickson M, Stafkey-Mailey DR University of South Carolina, Columbia, SC, USA

PIN77	THOUGHTS ON THE LABORATORY CULTURES REIMBURSED BY THE SOCIAL SECURITY IN AUSTRIA (OUTPATIENT SECTOR IN PHYSICIANS' CARE AND INSTITUTES, BUT NOT HOSPITAL OUTPATIENT CARE)
	Wilbacher I, Endel G Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria

PIN78	DIRECT MONTHLY HAART SUPPLY AT THE AIDS CENTER - A COST-EFFECTIVE MODE TO INCREASE ADHERENCE AND OUTCOME
	Elbirt D¹, Asher I¹, Cohen Y¹, Gradstein S¹, Werner B¹, Burke M¹, Hammerman A², Klang SH², Sthoeger Z¹ ¹Kaplan Medical Center, Rehovot, Israel, ²Clalit Health Services, Tel-Aviv, Israel

PIN79	SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF PALIVIZUMAB IN HIGH-RISK PATIENTS
	Paladio Duran N¹, García-Altés A², Pons Ràfols JM¹, Tebé Cordomí C¹ ¹Catalan Agency of Health Technology Assessment and Research, Barcelona, Spain, ²Fundación Instituto de Investigación en Servicios de Salud, Barcelona, Spain

PIN80	THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH TECHNOLOGY ASSESSMENT (HTA) OF VACCINES – LESSONS LEARNED FROM FINLAND
	Laine J¹, Soini EJ², Martikainen JA³ ¹Wyeth, Vantaa, Finland, ²ESiOR Oy, Kuopio, Finland, ³University of Kuopio, Kuopio, Finland

PIN81	MODELING AND SIMULATION OF EPIDEMIOLOGIC EFFECTS OF PENUMOCOCCAL CHILDREN VACCINATION IN AUSTRIA USING CLASSICAL MARKOVIAN METHODS AND DIFFERENTIAL EQUATIONS
	Endel G¹, Schiller - Frühwirth I¹, Urach C², Popper N², Zauner G² ¹Hauptverband der Österreichischen Sozialversicherungsträger, Vienna, Vienna, Austria, ²DWH - Simulation Services, Vienna, Vienna, Austria

PIN82	THE APPLICATION OF HEALTH TECNOLOGY ASSESSMENT ON THE NEW PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE IN ITALY
	La Torre G¹, Capri S², Castiglia P³, Anessi Pessina E⁴, Sacchini D⁵, Marocco A⁶, Gualano MR⁷, Mannocci A⁷, Nicolotti N⁷, Ricciardi W⁸ ¹Research centre of Health Engineering and Health Technology Assessment, Roma, Italy, ²Cattaneo-LIUC University, Castellanza, (Varese), Italy, ³University of Sassari, Sassari, Italy, ⁴Catholic University of the Sacred Heart, Rome , Italy, ⁵Catholic University of the Sacred Heart, Rome, Rome, Italy, ⁶GlaxoSmithKline Spa, Verona, Italy, ⁷Catholic University of the Sacred Heart, Rome, Italy, ⁸Catholic University of Sacred Heart, Roma, Italy

POSTER PRESENTATIONS SESSION III
SET-UP:	Tuesday, 27 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Tuesday, 27 October, 8:00 – 16:00
POSTER AUTHOR DISCUSSION HOUR:	Tuesday, 27 October, 11:00 – 12:00
DISMANTLE:	Tuesday, 27 October, 16:00 – 16:30

MUSCULAR-SKELETAL DISORDERS Clinical Outcomes Studies


PMS1	RISK ASSESSMENT OF CARDIOVASCULAR THROMBOTIC EVENTS, OTHER CARDIAC EVENTS, AND MORTALITY AMONG VETERANS AFFAIRS PATIENTS WITH DIFFICULT TO MANAGE GOUT
	Raisch DW¹, Rice J², Campbell HM² ¹University of New Mexico College of Pharmacy, Albuquerque, NM, USA, ²Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA

PMS2	SAFETY OF LEFLUNOMIDE, METHOTREXATE AND SULFASALAZINE: ANALYSIS OF DATA FROM WHO PROGRAMME FOR INTERNATIONAL DRUG MONITORING
	Golicki D¹, Lis J², Niewada M¹ ¹Medical University of Warsaw, Warsaw, Poland, ²Sanofi-Aventis, Warsaw, Poland

PMS3	PROPORTION OF PATIENTS WITH OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN PERFORMING A BONE MINERAL DENSITY DIAGNOSIS MEASUREMENT: THE PRESAGE STUDY
	Guggenbuhl P¹, Dufour R², Liu-Leage S³, Tcherny S³, Sapin H³, Cortet B⁴ ¹CHU Rennes, Rennes, France, ²Institut sainte catherine, Avignon, France, ³Lilly France, Suresnes, France, ⁴CHRU Lille, Lille, France

PMS4	EUROQOL-5 DIMENSION HEALTH STATUS QUESTIONNAIRE RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED PHASE 3 STUDY OF TAPENTADOL EXTENDED RELEASE (ER) FOR THE MANAGEMENT OF CHRONIC OSTEOARTHRITIS KNEE PAIN
	Kavanagh S¹, Ashworth J², Lange B², Etropolski MS³, Van Hove I⁴, Rauschkolb C³ ¹Johnson & Johnson Pharmaceutical Services, Beerse, Belgium, ²Grünenthal GmbH, Aachen, Germany, ³Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA, ⁴Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, N.V., Beerse, Belgium

PMS5	A SYSTEMATIC REVIEW AND MIXED TREATMENT COMPARISON (MTC) OF THE EFFICACY OF PHARMACOLOGICAL TREATMENTS FOR FIBROMYALGIA
	Choy E¹, Marshall D², Gabriel Z³, Mitchell S⁴, Gylee E⁵, Dakin HA⁶ ¹King's College LondonAcademi, Department of Rheumatology, London, UK, ²Inverclyde Royal Hospital, Greenock, UK, ³Pfizer Ltd, Surrey, Hertfordshire, UK, ⁴Abacus International, Bicester, UK, ⁵Abacus International, Oxfordshire, UK, ⁶Health Economics Research Centre, Oxford, Oxfordshire, UK

PMS6	HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI) SCORES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOCILIZUMAB PLUS CONVENTIONAL ANTI-RHEUMATIC DRUGS
	van Vollenhoven R¹, Ducournau P², Wintfeld N³, Berger W², Alten R⁴ ¹Karolinska Institutet, Stockholm, Sweden, ²Hoffmann-La Roche, Basel, Switzerland, ³Hoffmann-La Roche, Nutley, NJ, USA, ⁴Schlosspark-Klinik, Berlin, Germany

PMS7	DOSING PATTERN COMPARISON BETWEEN DULOXETINE AND PREGABALIN AMONG PATIENTS WITH FIBROMYALGIA
	Sun P¹, Watson PR², Mitchell BD², Zhao Y² ¹Kailo Research Group, Indianapolis, IN, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PMS8	PREVALENCE OF FIBROMYALGIA IN RUSSIA
	Le Lay K, Taieb C PFSA, Boulogne , France

PMS9	SECULAR DECREASES IN OSTEOPOROTIC FRACTURE RATES 1986-2006: A POPULATION-BASED ANALYSIS
	Leslie WD¹, Morin S², Azimaee M¹, Lix L³, Metge C¹, Caetano P¹ ¹University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montreal, QC, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada

PMS10	RECURRENT FRACTURES AFTER FIRST HIP FRACTURES POSHIP(PREVENTION OF SECOND HIP FRACTURES) STUDY
	Yamabe K¹, Hagino H¹, Sawaguchi T², Endo N³, Nakano T⁴, Watanabe Y⁵, Ito Y¹, Abe M¹ ¹POSHIP Secretariat, Tottori University, Yonago City, Tottori, Japan, ²Toyama City Hospital, Toyama, Toyama, Japan, ³Niigata University Graduate School of Medical and Dental Sciences, Niigata , Niigata , Japan, ⁴Tamana Central Hospital, Kumamoto, Kumamoto, Japan, ⁵Teikyo University, Tokyo, Tokyo, Japan

PMS11	LONG-TERM MORTALITY RATES AFTER INCIDENT FRACTURES IN A POPULATION-BASED COHORT OF MEN AND WOMEN
	Morin S¹, Azimaee M², Lix L³, Metge C², Caetano P², Leslie WD² ¹McGill University, Montreal, QC, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada

MUSCULAR-SKELETAL DISORDERS Cost Studies
PMS12	PROBABILISTIC ANALYSIS OF BUDGETARY IMPACT: GLUCOSAMINE IN KNEE OSTEOARTHRITIS TREATMENT
	Leartsakulpanitch J, Sakulbumrungsil R Chulalongkorn University, Bangkok, Thailand

PMS13	BUDGETARY IMPACT OF A NEW URATE-LOWERING THERAPY (ULT) FOR THE TREATMENT OF GOUT IN A US HEALTH PLAN FORMULARY
	Pandya BJ¹, Quimbo R², Mody R¹, Srikanth S², Dabbous O¹ ¹Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, ²HealthCore, Inc., Wilmington, DE, USA

PMS14	MODELING THE PROGRESSION OF RHEUMATOID ARTHRITIS IN ITALY: BUDGET IMPACT ANALYSIS FOR BIOLOGIC AGENTS
	Di Matteo S, Colombo GL SAVE Studi Analisi Valutazioni Economiche, Milano, Milan, Italy

PMS15	ECONOMIC IMPACT OF BIOTHERAPIES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN FRANCE
	Maravic M Hopital Leopold Bellan, Paris, France

PMS16	BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
	Saggia MG, Santos EA Roche Brazil, Sao Paulo, SP, Brazil

PMS17	BUDGET IMPACT ANALYSIS OF REIMBURSEMENT OF ARAVA® (LEFLUNOMIDE) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND
	Kawalec P¹, Gierczynski J², Lis J², Glasek M² ¹Centrum HTA, Krakow, Poland, ²Sanofi-Aventis, Warsaw, Poland

PMS18	MANAGEMENT AND COST OF SCIATICA IN-HOSPITAL
	Dinet J¹, Poullie AI¹, Malafaye N², Aubas P², Dujols P², Cyteval C³ ¹Innovations & Health Economics Unit, University Hospital of Montpellier, Montpellier, France, ²Medical Information Unit, University Hospital of Montpellier, Montpellier, France, ³Radiology Dept, University Hospital of Montpellier, Montpellier, France

PMS19	BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
	Saggia MG, Santos EA Roche Brazil, Sao Paulo, SP, Brazil

PMS20	COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF INTRA-ARTICULAR SODIUM HYALURONATE VERSUS TOTAL ARTHROPLASTY IN THE TREATMENT OF KNEE OSTEOARTHRITIS UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
	Fernandes RA¹, Quintella FF¹, Teich V¹, Carvalho JCN², Molinari MB³, Krambek MC⁴ ¹MedInsight, Rio de Janeiro, RJ, Brazil, ²General Practice, Sao Paulo, SP, Brazil, ³Gynecology and Obstetrics, Sao Paulo, SP, Brazil, ⁴Anesthesiology, Sao Paulo, SP, Brazil

PMS21	MIXED TREATMENT COMPARISONS : AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA®) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
	Launois R¹, Riou França L¹, Maunoury F², Boissier MC³, Florentin V⁴ ¹REES France, Paris, France, ²STATESIA, Le Mans, France, ³APHP Paris, Bobigny, Ile de France, France, ⁴Roche, Neuilly sur Seine, France

PMS22	A COST-OF-ILLNESS STUDY OF PSORIATIC ARTHRITIS IN SPAIN
	Moreno JC¹, Daudén E², Rodriguez-Valverde V³, Gomez-Reino J⁴, Gratacos J⁵, Sabater FJ⁶, Casado MA⁷ ¹Hospital Reina Sofía, Córdoba, Andalucía, Spain, ²Hospital La Princesa, Madrid, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Complexo Hospitalario Universitario, Santiago de Compostela, Galicia, Spain, ⁵Hospital Parc Taulí, Sabadell, Cataluña, Spain, ⁶Schering-Plough S.A, Alcobendas, Spain, ⁷Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain

PMS23	COST OF ILLNESS IN AMYOTROPHIC LATERAL SCLEROSIS, MYASTHENIA GRAVIS AND FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
	Winter Y¹, Schepelmann K¹, Spottke A², Claus D³, Grothe A², Schröder R², Heuss D⁴, Vielhaber S⁵, Mylius V¹, Reese JP¹, Kiefer R⁶, Schrank B⁷, Oertel WH¹, Dodel R¹ ¹Philipps-University, Marburg, Germany, ²Friedrich-Wilhelms-University, Bonn, Germany, ³Klinikum Darmstadt, Darmstadt, Germany, ⁴Friedrich-Alexander University, Erlangen, Germany, ⁵Otto-von-Guericke University, Magdeburg, Germany, ⁶University Muenster, Muenster, Germany, ⁷Clinic of Diagnostics, Wiesbaden, Germany

PMS24	THE SOCIAL AND ECONOMIC COSTS OF SPINA BIFIDA IN ITALY: A COST OF ILLNESS STUDY
	Colombo GL¹, Dieci MC², De Gennaro M³, Mosiello G³, Redaelli T⁴, Schioppa F⁴, Gatti C⁵, Vinci M¹, Di Matteo S¹ ¹SAVE Studi Analisi Valutazioni Economiche, Milano, Milan, Italy, ²ASBI - Associazione Spina Bifida Italia, Parma, Italy, ³Centro Spina Bifida,, Rome, Italy, ⁴Centro Spina Bifida,, Milan, Italy, ⁵Centro Spina Bifida, Parma, Italy

PMS25	MEDICAL RESOURCE UTILIZATION AND WORKDAYS LOST IN PATIENTS WITH FIBROMYALGIA
	Kleintjens J¹, Peeters P², Van Engen AK¹, Taylor-Stokes G³, Le Lay K⁴, Taieb C⁴ ¹Quintiles Consulting, Hoofddorp, The Netherlands, ²Quintiles Consulting, Levallois-Perret, France, ³Adelphi Group, -, UK, ⁴PFSA, Boulogne , France

PMS26	HEALTH CARE RESOURCES AND COSTS OF FIBROMYALGIA: A REVIEW OF THE EVIDENCE
	Desjardins B¹, Berbari J¹, Farah B², Azzabi-Zouraq I³, Iskedjian M² ¹PharmIdeas Research and Consulting Inc., Ottawa, ON, Canada, ²PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, ³PharmIdeas Research and Consulting Inc., Lyon, France

PMS27	DIRECT AND INDIRECT COSTS OF RHEUMATOID ARTHRITIS MANAGEMENT IN POLAND
	Ruszkowski J¹, Lesniowska J¹, Gierczynski J², Lis J², Glasek M² ¹Kozminski University, Warsaw, Poland, ²Sanofi-Aventis, Warsaw, Poland

PMS28	COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA
	Lamotte M¹, Maugars Y², Le Lay K³, Taieb C⁴ ¹IMS Health, Brussels, Belgium, ²Nantes University Hospital Centre, Nantes, France, ³PFSA, Boulogne-billancourt, France, ⁴PFSA, Boulogne , France

PMS29	HEALTH ECONOMIC COMPARISON OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA BEFORE AND AFTER DIAGNOSIS IN FIVE EUROPEAN COUNTRIES
	Lamotte M¹, Maugars Y², Le Lay K³, Taieb C³ ¹IMS Health, Brussels, Belgium, ²Nantes University Hospital Centre, Nantes, France, ³PFSA, Boulogne , France

PMS30	COST ANALYSIS OF BALLOON KYPHOPLASTY VERSUS NON SURGICAL MANAGEMENT FOR OSTEOPOROTIC VERTEBRAL FRACTURES IN GERMANY
	Eidt D¹, Greiner W² ¹Leibniz University of Hannover, Hannover, Germany, ²University of Bielefeld, Bielefeld, Germany

PMS31	COST OF TREATMENT COMPARISON OF TNF- INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN SOUTH AFRICA
	Scheijbeler H, Strydom GD Wyeth pharmaceuticals, Midrand, South Africa

PMS32	ASSESSMENT OF THE TOTAL DIRECT MEDICAL COST OF PATIENTS IN SECOND-LINE TNF INHIBITOR THERAPY AND OF THE RESPECT OF CLINICAL PRACTICE RECOMMENDATIONS
	Launois R¹, Letellier M², Maunoury F³, Boissier MC⁴, Florentin V⁵ ¹REES France, Paris, Paris, France, ²ALCIMED, Paris, Paris, France, ³STATESIA, Le Mans, France, ⁴APHP Paris, Bobigny, Ile de France, France, ⁵Roche, Neuilly sur Seine, France

PMS33	COST-BENEFIT ANALYSIS OF MANAGEMENT STRATEGIES TO REDUCE ROAD TRAFFIC INJURIES
	Srijariya W, Riewpaiboon A, Chaikledkaew U, Pongcharoensuk P Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand

PMS34	WITHDRAWN


PMS35	COST-EFFECTIVENESS OF BIOLOGIC THERAPEUTIC SEQUENCES FOR RHEUMATOID ARTHRITIS IN THE UK
	Emery P¹, Taylor P², Isaacs JD³, Drost P⁴, Dupont D⁴, Beresniak A⁵ ¹Leeds General Infirmary, Leeds, UK, ²Imperial College London, London, UK, ³Newcastle University, Newcastle Upon Tyne, UK, ⁴Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium, ⁵Data Mining International, Geneva, Switzerland

PMS36	COST-EFFECTIVENESS OF ZOLEDRONIC ACID ONCE-YEARLY INFUSION IN THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROTIC FRACTURES BASED ON COMPLIANCE AND NUMBER NEEDED TO TREAT APPROACH IN THE TURKISH HEALTH CARE SETTING
	Pala M, Göl D Novartis Pharma, Istanbul, Turkey

PMS37	DOES GENERIC ALENDRONATE REALLY SAVE MONEY IN THE TREATMENT OF OSTEOPOROSIS GIVEN SUB-OPTIMAL REAL LIFE COMPLIANCE? AN EXAMPLE FROM THE DANISH SETTING
	Ariely R¹, Tambour M², Olson M³ ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ²Novartis Sverige AB, Taby, Sweden, ³Novartis Pharma AG, Basel, Switzerland

PMS38	ECONOMIC ANALYSIS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR KNEE REPLACEMENT IN SPAIN
	Gonzalez-Rojas N¹, Vieta A², Monreal M³, Wolowacz SE⁴ ¹Boehringer Ingelheim, Sant Cugat del Vallés, Barcelona, Spain, ²IMS Health, Barcelona, Spain, ³Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, ⁴RTI-Health Solutions, Manchester, UK

PMS39	SEQUENTIAL COST-EFFECTIVENESS MODELLING OF DIFFERENT BIOLOGIC STRATEGIES IN RHEUMATOID ARTHRITIS IN TURKEY
	Beresniak A¹, Hamuryudan V², Inanc M², Pay S³, Yazici H², Ozdedeli S⁴, Drost P⁵, Dupont D⁶ ¹Data Mining International, Geneva, Switzerland, ²Istanbul University, Istanbul, Turkey, ³Gülhane Military Medical Academy, Ankara, Turkey, ⁴Bristol-Myers Squibb, Istanbul, Turkey, ⁵Bristol-Myers Squibb International Corporation, Braine-l'Alleud, Belgium, ⁶Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium

PMS40	COST-EFFECTIVENESS SIMULATION MODEL OF BIOLOGIC STRATEGIES FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS BASED ON DISEASE ACTIVITY IN GERMANY
	Beresniak A¹, Baerwald C², Zeidler H³, Gromnica-Ihle E⁴, Kruger K⁵, Neubauer AS⁶, Dupont D⁷, Merkesdal S⁸ ¹Data Mining International, Geneva, Switzerland, ²Universitätsklinikum Leipzig AöR, Leipzig, Germany, ³Rheumatologikum, Mitte, Hannover, Germany, ⁴-, Berlin, Germany, ⁵Praxiscentrum St. Bonifatius, Munich, Germany, ⁶Bristol-Myers Squibb, Munich, Germany, ⁷Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium, ⁸Medizinische Hochschule Hannover, Hannover, Germany

PMS41	COST-EFFECTIVENESS OF TNF-ALPHA BLOCKERS IN REAL-WORLD SETTING OF CZECH REGISTRY
	Dolezal T¹, Petrikova A², Pavelka K³ ¹Charles University, 3rd Medical Faculty, Prague, Czech Republic, ²University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic, ³Charles University, Rheumatology Institute, Prague, Czech Republic

PMS42	HEALTH ECONOMIC EVALUATION OF THE TREATMENT OF OSTEOPOROSIS IN FIVE ITALIAN REGIONS
	Baio G¹, Di Tanna GL², Integlia D³, Pammolli F⁴ ¹University College London, London, UK, ²University of Rome "La Sapienza", Rome, Italy, ³CERM, Rome, Italy, ⁴Institute for Advanced Studies, Lucca , Italy

PMS43	ECONOMIC EVALUATION OF GLUCOSAMINE SULPHATE TREATMENT IN KNEE OSTEOARTHRITIS
	Simoens S Katholieke Universiteit Leuven, Leuven, Belgium

PMS44	WITHDRAWN

PMS45	COST-EFFECTIVENESS OF BALLOON KYPHOPLASTY IN PATIENTS WITH SYMPTOMATIC VERTEBRAL COMPRESSION FRACTURES IN A UK SETTING
	Strom O¹, Leonard K², Cooper C³, Marsh D⁴ ¹i3 Innovus, Stockholm, Sweden, ²Medtronic UK, Watford, UK, ³University of Southampton, Southampton, UK, ⁴Institute of Orthopaedics and Musculoskeletal Science, UCL, London, UK

PMS46	INDIRECT COSTS OF RHEUMATOID ARTHRITIS BEFORE AND AFTER 6 MONTHS OF TREATMENT WITH BIOLOGICS: THE GISEA STUDY
	Lama N¹, Mancarella L², de Portu S³, Lapadula G⁴, Ferraccioli G², Mantovani LG⁵ ¹Second University of Naples, Naples, Italy, ²Catholic University of the Sacred Heart, Rome, Italy, ³University Federico II, Naples, Italy, ⁴University of Bari, Bari, Italy, ⁵University of Naples, Federico II, Naples, Italy

PMS47	POTENTIAL HEALTH ECONOMIC BENEFITS OF IMPROVING THE CARDIOVASCULAR SAFETY PROFILE OF NSAIDS
	Svedbom A¹, Pfister P², Miltenburger C³, Holmstrom S², Borgstrom F¹ ¹i3 Innovus, Stockholm, Sweden, ²NicOx, Sophia Antipolis Cedex, France, ³i3 Innovus, Berlin, Germany

PMS48	PHARMACOECONOMIC MODEL FOR TREATING OSTEOPOROSIS WITH ALPHACALCIDOL IN GERMANY
	Andersen SH, Ryttov J, Nielsen S LEO Pharma, Ballerup, Denmark

PMS49	COST-UTILITY ANALYSIS OF LEFLUNOMIDE (ARAVA) IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND
	Plisko R¹, Krzystek J¹, Lis J², Rys P¹ ¹HTA Consulting, Krakow, Poland, ²Sanofi-Aventis, Warsaw, Poland

PMS50	COST-MINIMIZATION ANALYSIS OF BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-VERTEBRAL FRACTURES UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
	Saggia MG, Paschoalin MA, Santos EA, Borges LG Roche Brazil, Sao Paulo, SP, Brazil

PMS51	COST-MINIMIZATION ANALYSIS OF IV BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-VERTEBRAL FRACTURES UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
	Saggia MG, Paschoalin MA, Santos EA, Borges LG Roche Brazil, Sao Paulo, SP, Brazil

PMS52	COST-MINIMIZATION ANALYSIS OF BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-VERTEBRAL FRACTURES UNDER THE PATIENT PERSPECTIVE IN BRAZIL
	Saggia MG, Paschoalin MA, Santos EA, Borges LG Roche Brazil, Sao Paulo, SP, Brazil

PMS53	ECONOMIC EVALUATION OF TRAMADOL/PARACETAMOL COMBINATION TABLETS VS NSAIDS FOR OSTEOARTHRITIS PAIN IN SPAIN
	Vidal J¹, Brosa M², Benito P³, Manresa A⁴, Ly-Pen D⁵, Nieves D², Batlle E⁶, Blanco F⁷, Collar JM⁸ ¹Hospital General Universitario de Guadalajara, Guadalajara, Spain, ²Oblikue Consulting, Barcelona, Spain, ³Hospital del Mar-IMAS, Barcelona, Spain, ⁴CAP Nou Tarraco, Tarragona, Spain, ⁵Centro de Salud Gandhi, Madrid, Spain, ⁶Hospital General Universitario de Alicante, Alicante, Spain, ⁷Hospital Juan Canalejo, La Coruña, Spain, ⁸Grunenthal Pharma, S.A., Madrid, Spain

PMS54	COST-EFFECTIVENESS OF TOCILIZUMAB COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN ITALY
	Diamantopoulos A¹, Wintfeld N², Giuliani G³ ¹Thema Reserach Ltd., London, UK, ²Hoffmann-La Roche Inc, Nutley, NJ, USA, ³Roche S.p.A. Italy, Monza, Italy

PMS55	COST UTILITY ANALYSIS OF TOPICAL DICLOFENAC FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE
	Lachaine J¹, Beauchemin C² ¹University of Montreal, Montréal, QC, Canada, ²University of Montreal, Montreal, QC, Canada

PMS56	COST-UTILITY OF AUTOLOGOUS CHONDROCYTES IMPLANTATION USING CHONDROCELECT^® IN SYMPTOMATIC KNEE CARTILAGE DAMAGE IN BELGIUM
	Gerlier L¹, Lamotte M¹, Wille M², Dubois D³ ¹IMS Health, Brussels, Belgium, ²TiGenix NV, Leuven, Belgium, ³Patient Value Solutions, Huldenberg, Belgium

PMS57	COST-UTILITY ANALYSIS OF BALLOON KYPHOPLASTY FOR PATIENTS WITH OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES IN JAPAN
	Kamae I¹, Kobayashi M², Togawa D³, Konno S⁴ ¹Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, ²Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan, ³Hakodate Central General Hospital, Hakodate, Hokkaido, Japan, ⁴Fukushima Medical University, Fukushima, Fukushima, Japan

PMS58	COST-UTILITY ANALYSIS OF DIFFERENT TREATMENT STRATEGIES AFTER THE FAILURE OF FIRST BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS (RA) IN THE FINNISH SETTING
	Hallinen TA¹, Soini EJ¹, Eklund K², Puolakka K³ ¹ESiOR Oy, Kuopio, Finland, ²Rheumatological Center of Helsinki, Helsinki, Finland, ³Lappeenranta Central Hospital, Lappeenranta, Finland

PMS59	THE CLINICAL AND ECONOMIC BURDEN OF NONADHERENCE WITH OSTEOPOROSIS MEDICATIONS
	Hiligsmann M, Rabenda V, Bruyère O, Reginster JY University of Liège, Liège, Belgium

PMS60	COST-UTILITY OF EXERCISE THERAPY IN ADOLESCENTS AND YOUNG ADULTS SUFFERING FROM THE PATELLOFEMORAL PAIN SYNDROME
	Tan S, van Linschoten R, van Middelkoop M, Koes B, Bierma-Zeinstra S, Koopmanschap M Erasmus MC, Rotterdam, The Netherlands

PMS61	SHORT-TERM DISABILITY ASSOCIATED WITH HIP, NON-VERTEBRAL, AND VERTEBRAL FRACTURES IN THE UNITED STATES
	Chung H¹, Jhaveri M², Skrepnek GH³ ¹Rutgers University, Piscataway, NJ, USA, ²sanofi-aventis USA, Bridgewater, NJ, USA, ³University of Arizona, Tucson, AZ, USA

PMS62	INDIRECT COSTS OF RHEUMATOID ARTHRITIS AND THEIR DETERMINANTS
	Maurel F¹, Bardoulat I¹, Camara C², Schadtler Law L³, Le Pen C⁴ ¹IMS Health, Puteaux, France, ²Wyeth Pharmaceuticals France, Paris La Défense , France, ³Wyeth Pharmaceuticals France, Paris La Défense Cedex, France, ⁴Dauphine University, Paris, France

PMS63	COMPARISON OF STAFF RESOURCES AND PATIENT TIME REQUIRED FOR RITUXIMAB AND INFLIXIMAB ADMINISTRATION IN 3 UK NHS HOSPITALS
	Scott DGI¹, Moots R², Dasgupta B³, De la Orden M⁴, Pulfer A⁵ ¹Norfolk and Norwich University Hospital, Norwich, Norfolk, UK, ²University of Liverpool, Liverpool, Merseyside, UK, ³Southend University Hospital, Westcliff on Sea , Essex, UK, ⁴Roche Products Limited, Welwyn Garden City, Hertfordshire, UK, ⁵pH Associates, Marlow, UK

PMS64	ANALYSIS OF HOSPITAL EVENTS MEANING IATROGENICITY, ANHEMIA
	Vainchtock A¹, Kosa M², Diazaraque R³, Lamarsalle L¹, Duru G⁴ ¹HEVA Health Evaluation, Lyon, France, ²PFIZER FRANCE, Paris, France, ³PFIZER, Walton Oaks, UK, ⁴Université Caude Bernard, Lyon, France

PMS65	IMPACT OF MINIMAL ACCESS SPINAL TECHNOLOGIES (MAST ^TM) ON HOSPITALIZATION COST: A FRENCH EXPERIENCE
	Lepeintre JF, Leclerc C Hopital FOCH, Suresnes, France

MUSCULAR-SKELETAL DISORDERSPatient-Reported Outcomes Studies
PMS66	GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE AND ASSOCIATED RISK OF FRACTURES IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES
	Claus V¹, Steinle T², Kostev K³, Intorcia M⁴ ¹IMS Health GmbH & Co. OHG, Munich, Germany, ²Amgen GmbH, Munich, Germany, ³IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany, ⁴Amgen Europe GmbH, Zug, Switzerland

PMS67	THE EFFECT OF MEDICATION CHOICE BETWEEN DULOXETINE AND PREGABALIN ON MEDICATION COMPLIANCE AND DIRECT CARE COSTS AMONG PATIENTS WITH FIBROMYALGIA
	Sun P¹, Watson PR², Mitchell BD², Zhao Y² ¹Kailo Research Group, Indianapolis, IN, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PMS68	GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES
	Claus V¹, Steinle T², Kostev K³, Intorcia M⁴ ¹IMS Health GmbH & Co. OHG, Munich, Germany, ²Amgen GmbH Germany, Munich, Germany, ³IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany, ⁴Amgen Europe GmbH, Zug, Switzerland

PMS69	ITEM REDUCTION AND VALIDATION OF A NEW ADHERENCE QUESTIONNAIRE IN OSTEOPOROTIC POST-MENOPAUSAL WOMEN: THE ADHERENCE EVALUATION OF OSTEOPOROSIS TREATMENT (ADEOS) QUESTIONNAIRE
	Cortet B¹, Legrand E², Breuil V³, Regnault A⁴, Dias-Barbosa C⁴, Roborel de Climens A⁵, Gaudin AF⁶, Cotte FE⁶ ¹CHRU Lille, Lille, France, ²CHU, Angers, France, ³CHU de Nice, Nice, France, ⁴Mapi Values France, Lyon, France, ⁵Mapi Values, Lyon, France, ⁶GlaxoSmithKline France, Marly le Roi, France

PMS70	USE OF QUALITATIVE RESEARCH TO ELICIT PATIENT-REPORTED OUTCOME APPROACHES IN OSTEOPOROSIS
	Alegre P¹, Marant C², Vigneux M², Seignobos E² ¹Servier, Suresnes, France, ²Mapi Values, Lyon, France

PMS71	PREDICTING CHANGES IN EQ-5D UTILITY SCORE VIA PASI OR HAQ IN PSORIATIC ARTHRITIS PATIENTS
	Zbrozek A¹, Kirkham B², Li W¹, Molta C¹, Singh A¹ ¹Wyeth Research, Philadelphia, PA, USA, ²University of New South Wales, Sydney , NSW , Australia

PMS72	A CALIBRATION OF THE RELATIONSHIP BETWEEN THE HAQ, THE SF-6D AND THE EQ-5D IN INFLAMMATORY ARTHRITIS
	Adams R¹, Walsh C², Tilson L¹, FitzGerald O³, Bresnihan B³, Veale D³, Barry M¹ ¹National Centre for Pharmacoeconomics, Dublin, Ireland, ²Trinity College Dublin, Dublin, Ireland, ³St Vincents University Hospital, Dublin, Ireland

PMS73	CONTENT VALIDITY OF THE FIBROMYALGIA SYNDROME BURDEN ASSESSMENT (FMBA©)
	Serra E¹, Spaeth M², Carbonell JA³, Arnould B⁴, Benmedjahed K⁵, Barnes N⁴, Le Lay K⁶, Taieb C⁶ ¹Amiens University Hospital, Amiens, France, ²Clinical Center for Rheumatology, Graefelfing/Muenchen, Germany, ³Hospital de la Esperanz, Barcelona, Spain, ⁴Mapi Values, Lyon, France, ⁵Mapi Values France, Lyon, France, ⁶PFSA, Boulogne , France

PMS74	DEVELOPMENT OF A TOOL TO HELP IN THE EARLY DETECTION OF FIBROMYALGIA (FM) IN GENERAL PRACTICE IN EUROPE
	Dias-Barbosa C¹, Guillemin I¹, Perrot S², Baron R³, Alegre C⁴, Choy E⁵, Cruccu G⁶, Desmeules J⁷, Margaux J⁸, Richards S⁹, Serra E¹⁰, Spaeth M¹¹, Arnould B¹ ¹Mapi Values, Lyon, France, ²Hôpital Hôtel Dieu Paris, Paris, France, ³Christian-Albrechts Universit, Kiel, Germany, ⁴Hospital General Universtiari, Barcelona, Spain, ⁵King's College, London, UK, ⁶La Sapienza University, Roma, Italy, ⁷Geneva University Hospital, Geneva, Switzerland, ⁸Erasme Hospital, Brussels, Belgium, ⁹Poole Hospital NHS Trust, Poole, UK, ¹⁰North Hospital, Amiens, France, ¹¹Rheumatology, Gräfelfing, Germany

PMS75	OAKHQOL, A DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR OSTEOARTHRITIS OF THE LOWER LIMB. VALIDITY AND RESPONSIVENESS
	Escobar A¹, González M¹, Sarasqueta C², Aizpuru F³, Herrera C⁴, García-Pérez L⁵ ¹Hospital de Basurto, Bilbao, Spain, ²Hospital Donostia, Donostia-San Sebastian, Spain, ³Hospital de Txagorritxu, Vitoria-Gasteiz, Spain, ⁴Hospital Virgen de las Nieves, Granada, Spain, ⁵Fundación Canaria de Investigación y Salud, Santa Cruz de Tenerife, Spain

PMS76	PATIENT REPORTED QUALITY-OF-LIFE ISSUES IN MYOTONIC DYSTROPHY TYPE-1 (DM1): A FIRST STEP IN THE DEVELOPMENT OF A DISEASE-SPECIFIC INSTRUMENT
	Heatwole C¹, Chin N¹, Hilbert J¹, Holloway R¹, Johnson N¹, Pandya S¹, Moxley R¹, Quinn C¹, Thornton C¹, Vickrey B², Victorson DE³ ¹The University of Rochester Medical Center, Rochester, NY, USA, ²The Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA, ³Northwestern University Feinberg School of Medicine/Evanston Northwestern Healthcare, Evanston, IL, USA

PMS77	FURTHER DEVELOPMENTS OF THE RHEUMATOID ARTHRITIS QUALITY OF LIFE SCALE (RAQOL)
	Wilburn J, McKenna SP, Twiss J Galen Research Ltd, Manchester, UK

PMS78	HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS
	Daudén E¹, Moreno JC², Gomez-Reino J³, Rodriguez-Valverde V⁴, Gratacos J⁵, Sabater FJ⁶, Casado MA⁷ ¹Hospital La Princesa, Madrid, Spain, ²Hospital Reina Sofía, Córdoba, Andalucía, Spain, ³Complexo Hospitalario Universitario, Santiago de Compostela, Galicia, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital Parc Taulí, Sabadell, Cataluña, Spain, ⁶Schering-Plough S.A, Alcobendas, Spain, ⁷Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain

PMS79	IS BODY-MASS-INDEX A PREDICTIVE FACTOR FOR CLINICAL OUTCOME IN PATIENTS WITH MONOSEGMENTAL LUMBAR FUSION?
	Tuschel A, Meissl M, Ogon M Orthopaedic Hospital Vienna Speising, Vienna, Austria

PMS80	ASSOCIATION BETWEEN ANXIETY AND HRQOL IN PATIENTS WITH LOWER LIMB OSTEOARTHRITIS
	González M¹, Escobar A¹, Herrera C², García-Pérez L³, Sarasqueta C⁴ ¹Hospital de Basurto, Bilbao, Spain, ²Hospital Virgen de las Nieves, Granada, Spain, ³Fundación Canaria de Investigación y Salud, Santa Cruz de Tenerife, Spain, ⁴Hospital Donostia, Donostia-San Sebastian, Spain

PMS81	HAQ-BASED UTILITIES USING EUROQOL, BRAZIER'S SHORT FORM-6D, AND VAS-QOL HAVE DIFFERENT VALUES AND MAY NOT ALL DISCRIMINATE ACROSS DISEASE SEVERITY AMONG A PORTUGUESE COHORT OF RHEUMATOID ARTHRITIS PATIENTS
	Benito-Garcia E¹, Pedro S¹, Vasconcelos J¹, Marques R¹, Rodrigues A¹, Chaves I¹, Drost P² ¹BioEPI, Oeiras, Portugal, ²Bristol-Myers Squibb International Corporation, Braine-l'Alleud, Belgium

PMS82	VALIDITY AND RELIABILITY OF A HEATH RELATED QUALITY OF LIFE QUESTIONNAIRE : SOCIAL FUNCTIONING SCALE FOR TURKISH MSDS PATIENTS
	Malhan S¹, Oksuz E¹, Baytar S², Aktekin L³, Tulunay FC⁴ ¹Baskent University, Ankara, Turkey, ²Baskent University, ankara, Turkey, ³Ankara Numune Training and Research Hospital, Ankara, Turkey, ⁴Ankara University Medical School, Ankara, Turkey

PMS83	COMPARISON OF A GENERIC UTILITY MEASURE (EQ-5D) AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS
	Brodszky V¹, Péntek M², Érsek K¹, Sebestyén A³, Boncz I⁴, Gulácsi L¹ ¹Corvinus University of Budapest, Budapest, Hungary, ²Flor Ferenc County Hospital, Kistarcsa, Hungary, ³National Health Insurance Fund Administration, Pécs, Hungary, ⁴University of Pécs, Pécs, Hungary

PMS84	IMPACT OF CERTOLIZUMAB PEGOL (CZP) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL): RHEUMATOID ARTHRITIS (RA) PATIENTS APPROACH POPULATION US NORMS IN MENTAL HEALTH AND VITALITY DOMAINS
	Strand V¹, Fleischmann R², Kvien TK³, Kavanaugh A⁴, Smolen J⁵, Wells AF⁶, Nikai E⁷, Coteur G⁷, Combe B⁸ ¹Stanford University, Portola Valley, CA, USA, ²Univeristy of Texas Southwestern Medical Center, Dallas, TX, USA, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University of California, San Diego, LaJolla, CA, USA, ⁵Medical University of Vienna, Vienna, Austria, ⁶Rosalind Franklin University of Medicine and Science, Oak Creek, WA, USA, ⁷UCB, Brussels, Belgium, ⁸Hopital Lapeyronie, Montpellier, France

PMS85	EQ-5D VISUAL ANALOGUE SCALE (VAS) AND UTILITY INDEX VALUES IN FRENCH WOMEN WITH A DIAGNOSIS OF POST-MENOPAUSAL OSTEOPOROSIS
	Rajzbaum G¹, Lespessailles E², Gasquet I³, Branchoux S⁴, Cotte FE⁴ ¹Saint Joseph Hospital, Paris, France, ²CHR Orleans, Orleans, France, ³Inserm U669, Villejuif, France, ⁴GlaxoSmithKline France, Marly le Roi, France

PMS86	CERTOLIZUMAB PEGOL DEMONSTRATES SIGNIFICANT IMPROVEMENTS IN THE PRODUCTIVITY OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PARTICULARLY IN THE HOUSEHOLD
	Smolen J¹, Purcaru O², Emery P³ ¹Medical University of Vienna, Vienna, Austria, ²UCB, Brussels, Belgium, ³Leeds General Infirmary, Leeds, UK

PMS87	IMPACT OF RHEUMATOID ARTHRITIS (RA) ON WORKING CONDITIONS AND INCOME
	Maurel F¹, Fautrel B², Maravic M³, Bardoulat I¹, Preiss P⁴, Camara C⁵, Schadtler Law L⁶, Le Pen C⁷ ¹IMS Health, Puteaux, France, ²Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ³Hopital Leopold Bellan, Paris, France, ⁴Association Française des Polyarthritiques, Paris, France, ⁵Wyeth Pharmaceuticals France, Paris La Défense , France, ⁶Wyeth Pharmaceuticals France, Paris La Défense Cedex, France, ⁷Dauphine University, Paris, France

MUSCULAR-SKELETAL DISORDERSHealth Care Use & Policy Studies
PMS88	MANAGEMENT AND COST OF LOW BACK PAIN IN-HOSPITAL: HOW A LONGITUDINAL HOSPITAL DATA BASE DESCRIBES THE REAL PRACTICES ?
	Dinet J¹, Poullie AI¹, Malafaye N², Aubas P², Dujols P², Cyteval C³ ¹Innovations & Health Economics Unit, University Hospital of Montpellier, Montpellier, France, ²Medical Information Unit, University Hospital of Montpellier, Montpellier, France, ³Radiology Dept, University Hospital of Montpellier, Montpellier, France

PMS89	MANAGEMENT AND COST OF LUMBAGO-SCIATICA IN-HOSPITAL: HOW A LONGITUDINAL HOSPITAL DATA BASE DESCRIBES THE REAL PRACTICES ?
	Dinet J¹, Poullie AI¹, Malafaye N², Aubas P², Dujols P², Cyteval C³ ¹Innovations & Health Economics Unit, University Hospital of Montpellier, Montpellier, France, ²Medical Information Unit, University Hospital of Montpellier, Montpellier, France, ³Radiology Dept, University Hospital of Montpellier, Montpellier, France

PMS90	FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS' DISEASE MANAGEMENT
	Le Lay K, Taieb C PFSA, Boulogne , France

PMS91	ADHERENCE IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO) TREATED WITH ORAL BISPHOSPHONATES IN GERMANY: A SYSTEMATIC REVIEW
	Steinle T¹, Dieudonné G² ¹Amgen GmbH, Munich, Germany, ²Kompetenz: Gesundheit, Blaustein, Germany

PMS92	EXPOSURE TO OSTEOPOROSIS MEDICATION IN MEN
	Vytrisalova M, Blazkova S Charles University in Prague, Hradec Kralove, Czech Republic

PMS93	GREEK NHS CAPACITY CONSTRAINTS REGARDING IV TREATMENT FOR RHEUMATOID ARTHRITIS PATIENTS
	Athanasakis K, Detsis M, Kyriopoulos J National School of Public Health, Athens, Greece

PMS94	MANAGEMENT AND DIAGNOSIS OF OSTEOPOROTIC VERTEBRAL FRACTURES ACCORDING TO PRIMARY CARE PHYSICIANS
	Palma Ruiz M, Conde Espejo P, Amate J, Bouza C Instituto de Salud Carlos III, Madrid, Spain

PMS95	REAL WORLD DATABASE ANALYSIS: USAGE AND ECONOMIC IMPACT OF ANTI-TNFS AS SECOND LINE THERAPY FOR RHEUMATOID ARTHRITIS PATIENTS IN THE PUBLIC HEALTHCARE SECTOR IN BRAZIL
	Saggia MG, Santos EA, Borges LG, Aguiar R Roche Brazil, Sao Paulo, SP, Brazil

PMS96	ARE THE ADMINISTRATIVE DATABASE A STRATEGIC TOOL IN DECISION MAKING? CASE STUDY: RHEUMATOID ARTHRITIS IN PIEMONTE REGION
	Roggeri DP¹, Berti V², Canonico PL¹ ¹University of Piemonte Orientale, Novara, Novara, Italy, ²Assessorato Tutela Salute e Sanità - regione Piemonte, Torino, , Italy

PMS97	FACTORS INFLUENCING REIMBURSEMENT AND PRESCRIPTION DECISIONS ON THE RHEUMATOID ARTHRITIS MAKET IN GERMANY, SPAIN, ITALY, FRANCE AND UK
	Ilgin Y¹, Pleguezuelo Witte M² ¹IMS Health, Frankfurt, Germany, ²IMS Health, London, UK

PMS98	DEVELOPMENT AND VALIDATION OF A DISEASE MODEL FOR POST-MENOPAUSAL OSTEOPOROSIS
	Gauthier A¹, Kanis JA², Martin M³, Compston J⁴, Borgstrom F⁵, Cooper C⁶ ¹Amaris, London, UK, ²University of Sheffield, Sheffield, Sheffield, UK, ³i3 Innovus, Uxbridge, Middlesex, UK, ⁴University of Cambridge, Cambridge, Cambridgeshire, UK, ⁵i3 Innovus, Stockholm, Sweden, ⁶University of Southampton, Southampton, UK

PMS99	MANAGEMENT OF KNEE OSTEOARTHRITIS: IMPACT ON PAIN ON A DAILY BASIS
	Dreiser RL¹, Taieb C² ¹Rheumatologist, Paris, France, ²PFSA, Boulogne , France

POSTER PRESENTATIONS SESSION III
SET-UP:	Tuesday, 27 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Tuesday, 27 October, 8:00 – 16:00
POSTER AUTHOR DISCUSSION HOUR:	Tuesday, 27 October, 11:00 – 12:00
DISMANTLE:	Tuesday, 27 October, 16:00 – 16:30

SENSORY SYSTEMS DISORDERSClinical Outcome Studies
PSS1	VERTEPORFIN IN NEOVASCULAR AMD: REAL LIFE CONFIRMS CLINICAL TRIALS RESULTS
	Sambuc R¹, Le Pen C², Soubrane G³, Quentel G⁴, Zerouta S⁵, Ponthieux A⁵ ¹University of Aix-Marseille II, Faculty of Medicine, Marseille, France, ²Dauphine University, Paris, France, ³Centre Hospitalier Intercommunal de Créteil, Créteil, France, ⁴Imaging and Laser centre, Paris, France, ⁵Novartis Pharma, Rueil-Malmaison, France

PSS2	COMPARISON OF OUTCOMES FOR MULTIFOCAL INTRA-OCULAR LENSES (MIOLS) : A META-ANALYSIS
	Berdeaux G¹, Lafuma A², Courouve L³, Khoshnood B⁴ ¹Conservatoire National des Arts et Métiers, Paris, Hauts de Seine, France, ²Cemka, Bg la reine, Hauts de Seine, France, ³Cemka eval, Bourg la Reine, Hauts de Seine, France, ⁴Cemka Eval, Bourg la Reine, Hauts de Seine, France

PSS3	TREATMENT PERSISTENCY OF XALATAN-XALACOM, LUMIGAN-GANFORT AND TRAVATAN-DUOTRAV: AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE
	Berdeaux G¹, Lafuma A², Robert J³ ¹Conservatoire National des Arts et Métiers, Paris, Hauts de Seine, France, ²Cemka, Bg la reine, Hauts de Seine, France, ³CEMKA-EVAL, Bourg la Reine, France

PSS4	SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF ACTINIC KERATOSES
	Walczak J, Nogas G, Chmiel M, Kowalska M Arcana Institute, Cracow, Poland

PSS5	RESTOR® VERSUS ACRILISA® : ND-YAG LASER INCIDENCE RATE COMPARISON 18 MONTHS AFTER SURGERY
	Gauthier L¹, Lafuma A², Laurendeau C³, Berdeaux G⁴ ¹Polyclinique Côte Basque Sud, Saint jean de Luz, France, ²Cemka, Bg la reine, Hauts de Seine, France, ³Cemka-Eval, Bourg-la-Reine, France, ⁴Conservatoire National des Arts et Métiers, Paris, Hauts de Seine, France

PSS6	CONJUNCTIVAL HYPERAEMIA ASSOCIATED WITH THE FIXED COMBINATIONS OF LATANOPROST/TIMOLOL AND BIMATOPROST/TIMOLOL IN THE TREATMENT OF OCULAR HYPERTENSION OR GLAUCOMA
	Vinuesa MJ¹, Vinuesa I², Díaz S³, Martin I³, Soto J³, Fernandez-Arias I³ ¹Salamanca University, Salamanca, , Spain, ²Hospital Punta de Europa, Algeciras, Cádiz, Spain, ³Pfizer, Madrid, Spain

PSS7	THE APPLICATION OF DISCRETE EVENT SIMULATION TO QUANTITATIVE RISK BENEFIT ANALYSIS
	Maguire A¹, Douglas I², Blak BT³ ¹United BioSource Corporation, London, London, UK, ²London School of Hygiene and Tropical Medicine, London, UK, ³CSD EPIC, London, UK

SENSORY SYSTEMS DISORDERSCost Studies
PSS8	COSTS-OF-ILLNESS OF ULCUS CRURIS IN GERMANY: RESULTS OF TWO APPROACHES
	Purwins S¹, Augustin M¹, Herberger K¹, Debus S², Rustenbach SJ¹ ¹University Clinics of Hamburg, Hamburg, Germany, ²Asklepios Klinik Harburg, Hamburg, Germany

PSS9	COSTS OF PATIENTS WITH OCCUPATIONAL SEVERE CHRONIC HAND ECZEMA REFRACTORY TO TOPICAL CORTICOSTEROIDS FOR EMPLOYER'S MUTUAL INSURANCE COMPANIES IN SPAIN
	Mascaro JM¹, Querol I², Lindner L³, Prior M³, Oliver J⁴, Halbach RP⁴ ¹Servicio de Dermatología Hospital Universitario Clínic, Barcelona, Spain, ²Servicio de Dermatología MAZ, Zaragoza, Spain, ³IMS Health, Barcelona, Spain, ⁴Basilea Pharmaceuticals Iberia SL, Madrid, Spain

PSS10	COST OF MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN
	Sánchez-Carazo JL¹, Daudén E², Vanaclocha F³, Toribio J⁴, Pujol R⁵, Puig L⁶, Yébenes M⁷, Sabater FJ⁸ ¹Hospital General de Valencia, Valencia, Spain, ²Hospital La Princesa, Madrid, Spain, ³Hospital 12 de Octubre, Madrid, Spain, ⁴C.H.U. Santiago (Hospital Gil Casares), Santiago de Compostela, Spain, ⁵Hospital del Mar, Barcelona, Spain, ⁶Sant Pau, Barcelona, Spain, ⁷Pharmacoeconomics & Outcomes Research Iberia, Madrid, Madrid, Spain, ⁸Schering-Plough S.A, Alcobendas, Spain

PSS11	COST OF TREATMENT FAILURE IN ACUTE INFECTIOUS CONJUNCTIVITIS IN SCOTLAND, SPAIN, NETHERLANDS AND POTENTIAL ECONOMIC BENEFIT OF TOPICAL MOXIFLOXACIN 0.5%
	Robert J¹, Lafuma A², Verboven Y³, Brosa M⁴, Nuijten MJ⁵, Gylee E⁶ ¹Cemka, Bourg La Reine, France, ²Cemka, Bg la reine, Hauts de Seine, France, ³ALCON, Puurs, Belgium, ⁴Oblikue Consulting, Barcelona, Spain, ⁵Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands, ⁶Abacus, Londen, UK

PSS12	THE ECONOMIC IMPACTS OF ACUTE OTITIS MEDIA IN TAIWAN
	Wang PC¹, Chang CJ², Chang CH¹, Chuang LJ¹ ¹Cathay General Hospital, Taipei, Taiwan, ²Chang Gung University, Taoyuan, Taiwan

PSS13	CATARACT SURGERY COST IN PATIENTS WITH AND WITHOUT ASTIGMATISM: A FRENCH NATIONAL DRG DATABASE ANALYSIS
	Colin X¹, Lafuma A², Berdeaux G³ ¹Cemka-Eval, Bourg-La-Reine, France, ²Cemka, Bg la reine, Hauts de Seine, France, ³Conservatoire National des Arts et Métiers, Paris, Hauts de Seine, France

PSS14	A PATIENT SURVEY/CHART REVIEW STUDY ABOUT TREATMENT PATTERNS, COSTS AND QUALITY OF LIFE IN PATIENTS WITH PSORIASIS IN SWEDEN
	Hjortsberg C¹, Bergman A², Bjarnason A³, Hjelmgren J⁴, Svensson Å⁵, Ragnarson Tennvall G¹ ¹IHE, Lund, Sweden, ²The Swedish Institute for Health Economics, Lund, Sweden, ³Sahlgrenska Hospital, Gothenburg, Sweden, ⁴Janssen-Cilag AB, Sollentuna, Sweden, ⁵University of Lund, Malmö, Sweden

PSS15	COSTS OF GLAUCOMA IN DENMARK
	Olsen J¹, Berdeaux G² ¹University of Southern Denmark, Odense, Denmark, ²Conservatoire National des Arts et Métiers, Paris, Hauts de Seine, France

PSS16	DECISION MAKING ANALYSIS FOR DIFFERENT NEUROSENSORIAL DEEP HYPOACUSIA TREATMENTS IN COLOMBIA. COST-PRODUCTIVITY ASSESMENT
	Montes F¹, Castillo M² ¹Los Andes University, Bogota, Colombia, ²Universidad de Los Andes, Bogotá, Colombia

PSS17	A HEALTH ECONOMIC EVALUATION OF ELIMINATING NON-COMPLIANCE WITH ORAL TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS IN DOGS IN GERMANY
	Poulsen Nautrup B¹, Van Vlaenderen I², Gasper SM³ ¹EAH Consulting, Juelich, Germany, ²Deloitte, Diegem, Belgium, ³Pfizer Animal Health, Inc., New York, NY, USA

PSS18	A FRENCH ECONOMIC MODEL COMPARING COST-EFFECTIVENESS OF DUOTRAV AND XALACOM IN GLAUCOMA
	Lafuma A¹, Laurendeau C², Berdeaux G³ ¹Cemka, Bg la reine, Hauts de Seine, France, ²Cemka, Bourg-la-Reine, France, ³Conservatoire National des Arts et Métiers, Paris, Hauts de Seine, France

PSS19	CEFOVECIN AS TREATMENT OF SUPERFICIAL PYODERMA, WOUNDS AND ABSCESSES IN DOGS: ESTIMATION OF THE HEALTH AND ECONOMIC IMPACT OF ELIMINATING ORAL MEDICATION NON-COMPLIANCE IN THE UNITED STATES
	Van Vlaenderen I¹, Poulsen Nautrup B², Gasper SM³ ¹Deloitte, Diegem, Belgium, ²EAH Consulting, Juelich, Germany, ³Pfizer Animal Health, Inc., New York, NY, USA

PSS20	ECONOMIC EVALUATION OF BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PSORIASIS: ETANERCEPT COMPARED TO ADALIMUMAB AND INFLIXIMAB
	Webber JM¹, Lloyd AC¹, Lebmeier M², Conway P³ ¹IMS Health, London, UK, ²Wyeth Pharmaceuticals, Maidenhead, UK, ³Wyeth Europa, Berkshire, UK

PSS21	COST-EFFECTIVENESS OF A NEW TOPICAL PRESERVATIVE-FREE OPHTHALMIC ANTIBIOTIC TREATMENT WITH MOXIFLOXACIN IN THE NETHERLANDS
	Verboven Y¹, Robert J², Lafuma A³, Nuijten MJ⁴ ¹ALCON, Puurs, Belgium, ²CEMKA-EVAL, BOURG LA REINE, France, ³Cemka, Bg la reine, Hauts de Seine, France, ⁴Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands

PSS22	COST-EFFECTIVENESS STUDY OF COMPLICATED SKIN AND SKIN-STRUCTURE INFECTION TREATMENT IN MEXICO
	Baca-Muro VI¹, Soria-Cedillo IF², Olvera K³, Garcia-Contreras F⁴ ¹Research Consulting, Puebla, Mexico, ²Research Consulting, Hacienda Ojo de Agua, Mexico, ³Novartis Farmaceutica México, Mexico D.F., Mexico, ⁴Instituto Mexicano de Seguro Social, Mexico D.F., Mexico

PSS23	COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS NO TREATMENT IN ACTINIC KERATOSES
	Walczak J, Nogas G, Dybek-Karpiuk A, Kloc K, Labak M, Pawlik D Arcana Institute, Cracow, Poland

PSS24	COST EFFECTIVENESS ANALYSIS OF TAFLUPROST COMPARED WITH LATANOPROST ON THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA IN SOUTH KOREA
	Song HJ, Kang SH, Heo JH, Lee EK Sook Myung Women's University, Seoul, South Korea

PSS25	COST-EFFECTIVENESS OF BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PSORIASIS
	Carretero G¹, Moreno JC², Notario J³, Silvestre JF⁴, López-Belmonte JL⁵, Giménez E⁶, Sabater FJ⁷, Fonseca E⁸ ¹Hospital Dr. Negrín, Las Palmas de Gran Canarias, Las Palmas de Gr, Spain, ²Hospital Reina Sofía, Córdoba, Andalucía, Spain, ³Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain, ⁴Hospital General de Alicante, Alicante, Alicante, Spain, ⁵Schering Plough S.A, Alcobendas, Madrid, Spain, ⁶IMS Health, Barcelona, Spain, ⁷Schering-Plough S.A, Alcobendas, Spain, ⁸Complejo Hospitalario Universitario Juan Canalejo, A Coruña, A Coruña, Spain

PSS26	EXPECTED VALUE OF PARTIAL PERFECT INFORMATION IN A MARKOV MODEL OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE TYPE PSORIASIS
	Visser MS Erasmus MC, Rotterdam, The Netherlands

PSS27	A COST-UTILITY ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN ITALY
	Di Matteo S¹, Colombo GL² ¹S.A.V.E. Studi Analisi Valutazioni Economiche, Milan, Italy, ²SAVE Studi Analisi Valutazioni Economiche, Milan, Italy

PSS28	COST-EFFECTIVENESS OF USTEKINUMAB VERSUS ETANERCEPT IN SEVERE PLAQUE PSORIASIS PATIENTS: A CANADIAN PERSPECTIVE
	Brazier N¹, Pan F², Shear N³, Jivraj F¹, Schenkel B⁴, Brown R² ¹Janssen-Ortho, Inc., Toronto, ON, Canada, ²United BioSource Corporation, Bethesda, MD, USA, ³University of Toronto, Toronto, ON, Canada, ⁴J&J Pharmaceutical Services LLC, Horsham, PA, USA

SENSORY SYSTEMS DISORDERSPatient-Reported Outcomes Studies
PSS29	ADHERENCE TO ANTIGLAUCOMA DRUG TREATMENT IN NEWLY TREATED PATIENTS
	Moisan J, Fredette MJ, Duchesne T, Sirois C, Grégoire JP Université Laval, Québec, QC, Canada

PSS30	ETUD GLAUCOME, ETUDE TRANSVERSALE UN JOUR DANS LE GLAUCOME : ONE-DAY CROSS SECTIONAL STUDY IN GLAUCOMA
	Nordmann JP¹, Baudouin C², Bron A³, Denis P⁴, Renard JP⁵, Rouland JF⁶, Sellem E⁷, Estphan M⁸, Kosa M⁹ ¹Centre Hospitalier National des Quinze-Vingts, Paris, France, ²Centre Hospitalier National des Quinze Vingts, PARIS, France, ³Hôpital Général, Dijon, France, ⁴Hôpital Edouard Herriot, Lyon, France, ⁵Hôpital d'Instruction des Armées du Val de Grâce, Paris, France, ⁶Hôpital Huriez, Lille, France, ⁷Centre Ophtalmologique Kleber, Lyon, France, ⁸Pfizer France, Paris, France, ⁹PFIZER FRANCE, Paris, France

PSS31	LEVELS OF EMPOWERMENT AMONG PSORIATIC PATIENTS
	Pagliarello C, Di Pietro C, Tabolli S IDI IRCCS, Rome, Italy

PSS32	VALIDATION AND ASSESSMENT OF MEASUREMENT INVARIANCE OF THE EYELASH SATISFACTION QUESTIONNAIRE (ESQ) IN US CANCER PATIENTS
	Dang J¹, Hansen JE², Burgess SM³ ¹Consulting Measurement Group, Torrance, CA, USA, ²Allergan, Inc., Irvine, CA, USA, ³Allergan, Inc, Irvine, CA, USA

PSS33	DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PATIENTES WITH PSOARIASIS: ‘PSO-LIFE'
	Sánchez-Carazo JL¹, Daudén E², Herrera E³, Toribio J⁴, Puig L⁵, Sabater FJ⁶, Perulero N⁷, Badia X⁷ ¹Hospital General de Valencia, Valencia, Spain, ²Hospital La Princesa, Madrid, Spain, ³Hospital Universitario Virgen de la Victoria, Málaga, Spain, ⁴C.H.U. Santiago (Hospital Gil Casares), Santiago de Compostela, Spain, ⁵Sant Pau, Barcelona, Spain, ⁶Schering-Plough S.A, Alcobendas, Spain, ⁷IMS Health, Barcelona, Spain

PSS34	TOOLS TO HELP DIAGNOSIS OF ATOPIC DERMATITIS: A NEED IN PUBLIC HEALTH
	Taieb C PFSA, Boulogne , France

PSS35	DEVELOPMENT AND VALIDATION OF A TREATMENT SATISFACTION QUESTIONNAIRE OF HAND SKIN DISEASES: THE DERMSAT QUESTIONNAIRE
	Ruiz MA¹, Heras F², Alomar A³, Conde-Salazar L², De la Cuadra J⁴ ¹Universidad Autónoma de Madrid, Madrid, Spain, ²Escuela Nacional Medicina del Trabajo. Instituto Carlos III, Madrid, Spain, ³Hospital Sant Pau i Santa Creu, Barcelona, Spain, ⁴Hospital General Universitario, Valencia, Spain

PSS36	DEVELOPMENT AND VALIDATION OF THE PATIENT-REPORTED IMPACT OF SCARS MEASURE (PRISM)
	Wilburn J¹, McKenna SP¹, Brown B², Solomon M², McGrouther DA², Bayat A² ¹Galen Research Ltd, Manchester, UK, ²The University of Manchester, Manchester, UK

PSS37	QUALITY OF LIFE IN CHRONIC HAND ECZEMA AS MEASURED BY THE DERMATOLOGY LIFE QUALITY INDEX
	Freemantle N¹, Aldridge R², Stanley G³ ¹University of Birmingham, Birmingham, West Midlands, UK, ²University of Edinburgh, Edinburgh, Edinburgh, UK, ³Basilea Medical, Guildford, Surrey, UK

PSS38	INFLUENCE OF DEPRESSION ON HEALTH RELATED QUALITY OF LIFE IN PSORIASIS: RESULTS FROM AN OPEN LABEL STUDY OF ADALIMUMAB IN PATIENTS WITH PSORIASIS
	Qian H¹, Guh D¹, Papp K², Goyette A³, Teixeira H⁴, Zhang W¹, Bansback N⁵ ¹Centre for Health Evaluation and Outcomes Research, Vancouver, BC, Canada, ²K. Papp Clinical Research, Probity Medical Research, Waterloo, ON, Canada, ³Abbott, Saint-Laurent, QC, Canada, ⁴Abbott Canada, Saint-Laurent, QC, Canada, ⁵Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada

PSS39	PSORIASIS: AN EPIDEMIOLOGIC EVALUATION OF DISEASE BURDEN IN 590 PATIENTS
	Feneron D¹, Meyer N², Bardoulat I¹, Grandfils N¹, Thiriet C³, Camara C⁴, Sid-Mohand D⁵, Le Pen C⁶, Ortonne JP⁷ ¹IMS Health, Puteaux, France, ²CHU de Toulouse, Toulouse, France, ³Wyeth Pharmaceuticals, Paris La Defense, France, ⁴Wyeth Pharmaceuticals France, Paris La Défense , France, ⁵Association pour la lutte contre le psoriasis, Paris, France, ⁶Dauphine University, Paris, France, ⁷Hopital Archet II, Nice, France

PSS40	CAN WE RELY ON SCORES FROM THE DERMATOLOGY LIFE QUALITY INDEX?
	Twiss J, McKenna SP, Preston E, Meads DM Galen Research, Manchester, UK

PSS41	DEVELOPMENT AND ACCEPTABILITY OF A NEW INTERNATIONAL QUALITY OF LIFE INSTRUMENT SPECIFIC TO PHYSICAL APPEARANCE: BEAUTYQOL
	Beresniak A¹, Auquier P², Duru G³, Krueger GG⁴, Talarico S⁵, Tsutani K⁶, De Linares Y⁷, Berger G⁸ ¹Data Mining International, Geneva, Switzerland, ²Laboratoire de Santé Publique, Marseilles, France, ³National Centre of Scientific Research, Villeurbanne, France, ⁴University of Utah Health Sciences Center, Salt Lake City, UT, USA, ⁵Federal University of Sao Paulo, Sao Paulo, Brazil, ⁶University of Tokyo, Bunkyo, Tokyo, Japan, ⁷L'Oréal International, Asnieres sur Seine, France, ⁸University Pierre & Marie Curie, Paris, France

SENSORY SYSTEMS DISORDERSHealth Care Use & Policy Studies
PSS42	INTERVENTIONAL PROCEDURES IN GLAUCOMA: RESOURCES AND COSTS IN FIVE EUROPEAN COUNTRIES
	Lafuma A¹, Verboven Y², Darba J³, Brueggenjuergen B⁴, Gylee E⁵, Berto P⁶ ¹Cemka, Bg la reine, Hauts de Seine, France, ²ALCON, Puurs, Belgium, ³Universitat de Barcelona, Barcelona, Spain, ⁴Alphacare, Celle, Germany, ⁵Abacus International, Oxfordshire, UK, ⁶PBE consulting, Verona, Italy

PSS43	EVALUATION OF THE IMPLEMENTATION OF UK NATIONAL GUIDANCE ON THE USE OF BIOLOGICS IN SEVERE PSORIASIS
	Bewley A¹, Cerio R², Clement M³, Lucke T⁴, Orton D⁵, Walton S⁶, Allen S⁷ ¹Whipps Cross University Hospital, Leytonstone, London, UK, ²Royal London Hospital, Whitechapel, London, UK, ³Orpington Hospital, Orpington, London, UK, ⁴Royal Cornwall Hospital, Truro, Cornwall, UK, ⁵Amersham Hospital, Amersham, Buckinghamshire, UK, ⁶The Princess Royal Hospital, Hull, Kingston-Upon-Hu, UK, ⁷pH Associates, Marlow, Buckinghamshire, UK